AU2011208418B2

AU2011208418B2 - Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application

Info

Publication number: AU2011208418B2
Application number: AU2011208418A
Authority: AU
Inventors: Ahmed Abouabdellah; Antoine Ravet
Original assignee: Sanofi SA
Current assignee: Sanofi SA
Priority date: 2010-01-20
Filing date: 2011-01-19
Publication date: 2016-01-07
Anticipated expiration: 2031-01-19
Also published as: RU2012135525A; EP2526100B1; AR079934A1; JP5833570B2; US20120295909A1; CN102803258B; MX2012008377A; CA2787476C; KR20120125302A; WO2011089550A1; AU2011208418A1; SG182567A1; EP2526100A1; CA2787476A1; TW201139431A; US9000010B2; IL220859A0; CN102803258A; JP2013517323A; CN105837565A

Abstract

The invention relates to compounds corresponding to the general formula (I) : in which R

Description

1 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application A subject-matter of the invention is alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application. There still exists a need to find and develop products which are inhibitors of the enzyme FAAH (Fatty Acid Amide Hydrolase). The compounds of the invention meet this objective; and/or at least provide the public with a useful choice. Furthermore, these compounds have to exhibit metabolic and pharmacokinetic properties and a safety index which allow them to be used as medicaments. In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art. In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

2 Summary of the Invention The compounds of the invention correspond to the general formula (I): 0 R3 R2pw 2r N O ' R4 R'A (I) in which: - R 2 represents a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1

-

6 -alkyl, C 1

-

6 -alkoxy or -NR 8

R

9 group; - n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; - A represents a covalent bond, an oxygen atom, a C 1

-

6 -alkylene group or an -O-Ci_ 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group; - Ri represents an R 5 group optionally substituted by one or more R 6 and/or R 7 groups;

R

5 representing a group chosen from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, isobenzofuranyl, benzofuranyl, benzothiophenyl, benzothiadiazolyl, benzoxadiazolyl, indazolyl, indolizinyl, indolyl, isoindolyl, imidazopyridinyl, imidazopyrimidinyl, imidazopyrazinyl, imidazopyridazinyl, triazolopyridinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyrazinyl, pyrrolopyridazinyl, pyrrolotriazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyrazinyl, pyrazolopyridazinyl, furopyridinyl, furopyrimidinyl, 3 furopyrazinyl, furopyridazinyl, furotriazinyl, oxazolopyridinyl, oxazolopyrimidinyl, oxazolopyrazinyl, oxazolopyridazinyl, isoxazolopyridinyl, isoxazolopyrimidinyl, isoxazolopyrazinyl, isoxazolopyridazinyl, oxadiazolopyridinyl, thienopyridinyl, thienopyrimidinyl, thienopyrazinyl, thienopyridazinyl, thienotriazinyl, thiazolopyridinyl, thiazolopyrimidinyl, thiazolopyrazinyl, thiazolopyridazinyl, isothiazolopyridinyl, isothiazolopyrimidinyl, isothiazolopyrazinyl, isothiazolopyridazinyl or thiadiazolopyridinyl;

R

6 representing a halogen atom or a cyano, -CH 2 CN, nitro, hydroxyl, C 1

-

8 -alkyl, C 1

-

6 -alkoxy, Ci--thioalkyl, Ci- 6 -haloalkyl, Ci- 6 -haloalkoxy, Ci--halothioalkyl, C 3

-

7 -cycloalkyl,

C

3

-

7 -cycloalkyl-Ci_ 3 -alkylene, C 3

-

7 -cycloalkyl-Ci_ 3 -alkylene-O-, (CH 2 ) p-NR 8

R

9 , -NR 8

COR

9 , -NR 8

CO

2

R

9 , -NR 8

SO

2

R

9 , -NR 8

SO

2

NR

8

R

9 , -COR 8 , C0 2

R

8 , - (CH 2 ) p-CONR 8

R

9 , -S0 2

R

8 , -SO 2

NR

8

R

9 or -0- (Ci_ 3 -alkylene) -O group;

R

7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 )p-O-, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazopyrimidinyl, thienopyrimidinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, imidazopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, isoxazolopyridinyl or thiazolopyridinyl; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups which are identical to or different from one another; p representing a number which can have the value 0, 1, 2 or 3; - R 3 represents a hydrogen or fluorine atom, a C 1

-

6 -alkyl group 4 or a trifluoromethyl group; - R 4 represents a 5-membered heterocycle chosen from a furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, triazolyl or tetrazolyl; this heterocycle optionally being substituted by one or more substituents chosen from a halogen atom or a C 1 6 -alkyl, C 1 6 haloalkyl, C 3

-

7 -cycloalkyl, C 3

-

7 -cycloalkyl-Ci_ 3 -alkylene, C 1

-

6 haloalkoxy, cyano, -NR 8

R

9 , -NR 8 C (0) R 9 , -NR 8

CO

2

R

9 ,

-NR

8

SO

2

R

9 , -NR 8

SO

2

NR

8

R

9 , -C (O) R 8 , -C0 2

R

8 , -C (O) NR 8

R

9 , -C (0) N (R 8 ) (Ci_ 3 -alkylene-NRioRii), -S0 2

R

8 , -SO 2

NR

8

R

9 or -0- (Ci_ 3 alkylene)-0- group;

R

8 and R 9 representing, independently of one another, a hydrogen atom or a C 1

-

6 -alkyl group, or forming, with the nitrogen atom or atoms which carry them, in the case of NR 8

R

9 , a ring chosen from the azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine, oxazepine or piperazine rings, this ring optionally being substituted by a C 1

-

6 -alkyl or benzyl group; in the case of NR 8

COR

9 , a lactam ring; in the case of NR 8

CO

2

R

9 , an oxazolidinone, oxazinone or oxazepinone ring; in the case of NR 8

SO

2

R

9 , a sultam ring; in the case of NR 8

SO

2

NR

8

R

9 , a thiazolidine dioxide or thiadiazinane dioxide ring; Rio and R 11 representing, independently of one another, a hydrogen atom or a C 1 6 -alkyl group; with the exclusion of the following compound: 5-methylisoxazol-3-ylmethyl 4-hydroxy-4-(4-chlorophenyl) piperidine-1-carboxylate, in the form of the base or of an addition salt with an acid. The invention also relates to a process for the preparation of a compound of the invention, comprising reacting an amine derivative, a compound of following general formula (II): 5 R2 NH R 1

-

AY N in which R 1 , R 2 , A, n and m are as defined above, with a carbonate of following general formula (III): z0 O R 4 (IlI) in which Z represents a hydrogen atom or a nitro group and R 3 and R 4 are as defined above, in the presence of a base, in an organic solvent, at a temperature between ambient temperature and the reflux temperature of the solvent. The invention also provides a compound of the invention, in the form of a base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for the use thereof as medicament. The invention also provides a pharmaceutical composition comprising at least one compound of the invention, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, and optionally one or more pharmaceutically acceptable excipients. The invention also provides a compound of the invention in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for its use in the preparation of a medicament intended to prevent or to treat a pathology in which endogenous cannabinoids and/or any other substrate metabolized 6 by the enzyme FAAH are involved. The invention also provides a compound of the invention, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for its use in the preparation of a medicament intended to prevent or treat acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation. The invention also relates to a method of preventing or treating a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FAAH are involved, the method comprising administering to a patient an effectiv dose of a compound of the invention, in the form of the base or of an addition salt with a pharmaceutically acceptable acid or a hydrate or solvate of said compound. The invention also relates to a method of preventing or treating acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders 7 of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation, the method comprising administering to a patient an effective dose of a compound of the invention, in the form of the base or of an addition salt with a pharmaceutically acceptable acid or a hydrate or solvate of said compound. The invention also relates to a use of a compound of the invention, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, in the manufacture of a medicament for preventing or treating acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation in a patient.

8 Detailed Description The invention relates to compounds of general formula (I) as defined above. Among the compounds of general formula (I), a first subgroup of compounds is composed of the compounds for which R 2 represents a hydrogen atom. Among the compounds of general formula (I), a second subgroup of compounds is composed of the compounds for which m and n represent, independently of one another, the value 1 or 2. Among the compounds of general formula (I), a third subgroup of compounds is composed of the compounds for which m and n each represent the value 2. Among the compounds of general formula (I), a fourth subgroup of compounds is composed of the compounds for which A represents an -O-Ci_ 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group, in particular an -O-(CH 2

)

2 - group, also known as an ethyleneoxy group. Among the compounds of general formula (I) , a fifth subgroup of compounds is composed of the compounds for which A represents an -O-Ci_ 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group, in particular an -O-CH 2 - group, also known as a methyleneoxy group. Among the compounds of general formula (I), a sixth subgroup of compounds is composed of the compounds for which Ri represents an R 5 group optionally substituted by one or more R 6 9 and/or R 7 groups;

R

5 representing a group chosen from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, naphthyridinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, isobenzofuranyl, benzofuranyl, benzothiophenyl, indazolyl, indolizinyl, indolyl, isoindolyl, pyrrolopyridinyl, furopyridinyl or thienopyridinyl;

R

6 representing a halogen atom or a cyano, -CH 2 CN, nitro, hydroxyl, C 1

-

8 -alkyl, C 1

-

6 -alkoxy, Ci- 6 -thioalkyl, Ci- 6 -haloalkyl, Ci- 6 -haloalkoxy, Ci--halothioalkyl, C 3

-

7 -cycloalkyl,

C

3

-

7 -cycloalkyl-Ci_ 3 -alkylene, C 3

-

7 -cycloalkyl-Ci_ 3 -alkylene-O-, (CH 2 ) p-NR 8

R

9 , -NR 8

COR

9 , -NR 8

CO

2

R

9 , -NR 8

SO

2

R

9 , -NR 8

SO

2

NR

8

R

9 , -COR 8 , C0 2

R

8 , - (CH 2 ) p-CONR 8

R

9 , -S0 2

R

8 , -SO 2

NR

8

R

9 or -0- (Ci_ 3 -alkylene) -O group;

R

7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 )p-O-, pyridinyl, pyridazinyl, isoxazolyl, benzothiazolyl, pyrrolyl, pyrazolyl, tetrazolyl, pyrimidinyl, thiazolyl, pyrazinyl, triazinyl or benzoxazolyl; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups, which are identical to or different from one another, as defined above; p representing a number which can have the value 0, 1, 2 or 3;

R

8 and R 9 representing, independently of one another, a hydrogen atom or a C 1 6 -alkyl group; or forming, with the nitrogen atom(s) which carry them, in the case of NR 8

R

-

6 -alkyl or benzyl group; in the case of NR 8

COR

9 , a lactam ring; in the case of NR 8

CO

2

R

9 , an oxazolidinone, oxazinone or 10 oxazepinone ring; in the case of NR 8

SO

2

R

9 , a sultam ring; in the case of NR 8

SO

2

NR

8

R

9 , a thiazolidine dioxide or thiadiazinane dioxide ring. Among the compounds of general formula (I) , a seventh subgroup of compounds is composed of the compounds for which Ri represents an R 5 group optionally substituted by one or more R 6 and/or R 7 groups;

R

5 representing a group chosen from a phenyl, benzothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, cinnolinyl, naphthyridinyl or indolyl;

R

6 representing a halogen atom or a cyano, -CH 2 CN, nitro, hydroxyl, C 1

-

8 -alkyl, C 1

-

7 -cycloalkyl,

C

3

-

7 -cycloalkyl-Ci_ 3 -alkylene, C 3

-

7 -cycloalkyl-Ci_ 3 -alkylene-O-, (CH 2 )p-NR 8

R

9 , -NR 8

COR

9 , -NR 8

CO

2

R

9 , -NR 8

SO

2

R

9 , -NR 8

SO

2

NR

8

R

9 , -COR 8 , C0 2

R

8 , - (CH 2 ) p-CONR 8

R

9 , -S0 2

R

8 , -SO 2

NR

8

R

9 or -0- (Ci_ 3 -alkylene) -O group;

R

7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 )p-O-, pyridinyl, pyridazinyl, isoxazolyl, benzothiazolyl, pyrrolyl, pyrazolyl, tetrazolyl, pyrimidinyl, thiazolyl, pyrazinyl, triazinyl or benzoxazolyl; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups which are identical to or different from one another; p representing a number which can have the value 0, 1, 2 or 3;

R

8 and R 9 representing, independently of one another, a hydrogen atom or a C 1

-

6 -alkyl group, or forming, with the nitrogen atom which carries them, in the case of NR 8

R

9 , a ring chosen from azetidine, 11 pyrrolidine, piperidine, morpholine, thiomorpholine, azepine, oxazepine or piperazine rings, this ring optionally being substituted by a C 1 6 -alkyl or benzyl group; in the case of NR 8

COR

9 , a lactam ring; in the case of NR 8

CO

2

R

9 , an oxazolidinone, oxazinone or oxazepinone ring; in the case of NR 8

SO

2

R

9 , a sultam ring; in the case of NR 8

SO

2

NR

8

R

9 , a thiazolidine dioxide or thiadiazinane dioxide ring. Among the compounds of general formula (I) , an eighth subgroup of compounds is composed of the compounds for which Ri represents a group chosen from a phenyl, benzothiazolyl, naphthyl, quinolinyl, isoquinolinyl or indolyl, optionally substituted by one or more R 6 and/or R 7 groups;

R

6 representing a halogen atom or a cyano, C 1 8 -alkyl, C 1

-

6 alkoxy, Ci- 6 -haloalkyl, Ci- 6 -haloalkoxy, C 3

-

7 -cycloalkyl, - (CH 2 )p-NR 8

R

9 , -NR 8

COR

9 , -C0 2

R

8 , - (CH 2 )p-CONR 8

R

9 , -S0 2

R

8 or

-SO

2

NR

8

R

9 group;

R

7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 ) p-O-, isoxazolyl, benzothiazolyl, pyrrolyl, pyrazolyl, tetrazolyl, thiazolyl or benzoxazolyl; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups, which are identical to or different from one another, as defined above; p representing a number which can have the value 0 or 1;

R

8 and R 9 representing, independently of one another, a hydrogen atom or a C 1 6 -alkyl group; or else

R

8 and R 9 forming, with the nitrogen atom which carries them, in the case of -NR 8

R

9 , a morpholine ring; in the case of -NR 8

COR

9 , a lactam ring. Among the compounds of general formula (I) , a ninth subgroup 12 of compounds is composed of the compounds for which R 3 represents a hydrogen atom. Among the compounds of general formula (I) , a tenth subgroup of compounds is composed of the compounds for which R 4 represents a 5-membered heterocycle chosen from a pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl or isoxazolyl; this heterocycle optionally being substituted by one or more -C(0)NR 8

R

9 substituents in which R 8 and R 9 each represent a hydrogen atom. Among the compounds of general formula (I), an eleventh subgroup of compounds is composed of the compounds for which R 4 represents a 5-membered heterocycle chosen from a thiazolyl or isoxazolyl; this heterocycle optionally being substituted by one or more -C(0)NR 8

R

9 substituents in which R 8 and R 9 each represent a hydrogen atom. Among the compounds of general formula (I) , mention may be made of a twelfth subgroup represented by the compounds of formula (Ii): 0 Ri ,A )m " R (Ii) in which R 1 , A, R 4 , n and m are as defined above. Other subgroups composed of the compounds of formula (Ii) also come within the present invention. Thus, among the compounds of abovementioned general formula (Ii), a subgroup of compounds is composed of the compounds for 13 which A represents an -0- (CH 2

)

2 - group. Among the compounds of abovementioned general formula (Ii) , a subgroup of compounds is composed of the compounds for which A represents an -O-CH 2 - group. Among the compounds of general formula (I) , mention may be made of a thirteenth subgroup represented by the compounds of formula (Iii): 0 N O 0 R - )m S in which R 1 , A, n and m are as defined above. Other subgroups composed of the compounds of formula (Iii) also come within the present invention. Thus, among the compounds of abovementioned general formula (Iii), a subgroup of compounds is composed of the compounds for which A represents an -0-(CH 2

)

2 - group. Thus, among the compounds of abovementioned general formula (Iii), a subgroup of compounds is composed of the compounds for which A represents an -O-CH 2 - group. Among the compounds of general formula (I), a fourteenth subgroup is composed of the compounds of general formula (I) in which: - R 2 represents a hydrogen atom; - m and n represent, independently of one another, the value 1 or 2; 14 - A represents an -O-Ci- 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group, in particular an ethyleneoxy ou methyleneoxy group; - Ri represents a group chosen from a phenyl, benzothiazolyl, naphthyl, quinolinyl, isoquinolinyl or indolyl, optionally substituted by one or more R 6 and/or R 7 groups;

R

6 representing: - a halogen atom, in particular a chlorine, fluorine or bromine; - a cyano group; - a C 1

-

8 -alkyl group, in particular a methyl, isopropyl, 1,1,3,3-tetramethylbutyl or tert-butyl; - a C 1

-

6 -alkoxy group, in particular a methoxy, hexyloxy, butoxy, ethoxy; - a C 1

-

6 -haloalkyl group, in particular a trifluoromethyl, pentafluoroethyl; - a C 1

-

6 -haloalkoxy group, in particular a trifluoromethoxy or difluoromethoxy; - a C 3

-

7 -cycloalkyl group, in particular a cyclopentyl; - a - (CH 2 ) p-NR 8

R

9 group, in which p has the value 0 or 1; R 8 and R 9 each represent a hydrogen atom or R 8 and R 9 each represent a methyl, or else R 8 and R 9 form, with the nitrogen atom which carries them, a morpholine ring; - an -NR 8

COR

9 group, in which R 8 represents a hydrogen atom and R 9 represents a methyl, or else R 8 and R 9 form, with the nitrogen atom which carries them, a lactam ring, in particular a B-lactam ring; - a -C0 2

R

8 group, in which R 8 represents a methyl; - a - (CH 2 ) p-CONR 8

R

9 group, in which p has the value 0 or 1 and R 8 and R 9 each represent a hydrogen atom; - an -S0 2

R

8 group, in which R 8 represents a methyl; - an -SO 2

NR

8

R

9 group, in which R 8 and R 9 each represent a hydrogen atom;

R

7 representing a group chosen from a phenyl group; a 15 phenyl-Ci_ 4 -alkylene- group, in particular a 1,1-dimethyl-1 phenylmethylene or a benzyl; a phenyl-(CH 2 )p-O- group in which p has a value of 0 or 1; or an isoxazolyl, benzothiazolyl, pyrrolyl, pyrazolyl, tetrazolyl, thiazolyl or benzoxazolyl group; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups, which are identical to or different from one another, as defined above, such as a halogen atom or a cyano group; - R 3 represents a hydrogen atom; - R 4 represents a 5-membered heterocycle chosen from a thiazolyl or isoxazolyl; this heterocycle optionally being substituted by one or more -C(O)NR 8

R

9 substituents in which R 8 and R 9 each represent a hydrogen atom. Among the compounds of general formula (I), a fifteenth subgroup of compounds is composed of the compounds of general formula (I) in which, simultaneously, Ri and/or R 2 and/or R 3 and/or R 4 and/or n and/or m and/or A are as defined in the above subgroups. Among the compounds of general formula (I), the following compounds may be cited (IUPAC nomenclature generated by the AutoNom software): 1. Thiazol-2-ylmethyl 4-[2-(4-chloronaphth-1-yloxy)ethyl] piperidine-1-carboxylate 2. Thiazol-2-ylmethyl 4-[2-(4-fluorophenoxy)ethylipiperidine 1-carboxylate 3. Thiazol-4-ylmethyl 4-[2-(4-fluorophenoxy)ethylipiperidine 1-carboxylate 4. Thiazol-4-ylmethyl 4-[2-(4-{trifluoromethyl}phenoxy) ethyl]piperidine-1-carboxylate 5. Thiazol-4-ylmethyl 4-[2-(4-chlorophenoxy)ethylipiperidine 1-carboxylate 16 6. Thiazol-5-ylmethyl 4-[2-(4-fluorophenoxy)ethylipiperidine 1-carboxylate 7. Thiazol-5-ylmethyl 4-[2-(4-chlorophenoxy)ethylipiperidine 1-carboxylate 8. Thiazol-5-ylmethyl 4-[2-(4-{trifluoromethyl}phenoxy) ethyl]piperidine-1-carboxylate 9. Thiazol-4-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy)ethyl] piperidine-1-carboxylate 10. Thiazol-4-ylmethyl 4-[2-(4-cyanophenoxy)ethyl] piperidine-1-carboxylate 11. Thiazol-4-ylmethyl (+/-)-3-(6-methoxynaphth-2-yloxy methyl)pyrrolidine-1-carboxylate 12. Thiazol-4-ylmethyl (+/-)-3-(7-methoxynaphth-2-yloxy methyl)pyrrolidine-1-carboxylate 13. Thiazol-4-ylmethyl (+/-)-3-(3,4-dichlorophenoxy methyl)pyrrolidine-1-carboxylate 14. Thiazol-4-ylmethyl 4-[2-(6-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate 15. Thiazol-4-ylmethyl 4-[2-(naphth-2-yloxy)ethyl] piperidine-1-carboxylate 16. Thiazol-4-ylmethyl (+/-)-3-(4-chloronaphth-1-yloxy methyl)pyrrolidine-1-carboxylate 17. Thiazol-4-ylmethyl (+/-)-3-(naphth-2-yloxymethyl) pyrrolidine-1-carboxylate 18. Thiazol-4-ylmethyl 4-[2-(4'-fluorobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate 19. Thiazol-4-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl] piperidine-1-carboxylate and its hydrochloride 20. Thiazol-4-ylmethyl 4-[2-(isoquinolin-6-yloxy)ethyl] piperidine-1-carboxylate and its hydrochloride 17 21. Thiazol-4-ylmethyl (+/-)-3-(3'-cyanobiphenyl-3 yloxymethyl)pyrrolidine-1-carboxylate 22. Thiazol-4-ylmethyl (+/-)-3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine-1-carboxylate 23. Thiazol-4-ylmethyl (+/-)-3-(5-chloronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate 24. Thiazol-4-ylmethyl (+/-)-3-(3-{trifluoromethoxy} phenoxymethyl)pyrrolidine-1-carboxylate 25. Thiazol-4-ylmethyl (+/-)-3-[4-(1-methyl-1-phenyl ethyl)phenoxymethyl]pyrrolidine-1-carboxylate 26. Thiazol-4-ylmethyl (+/-)-3-(quinolin-3-yloxymethyl) pyrrolidine-1-carboxylate 27. Thiazol-4-ylmethyl (+/-)-3-(isoquinolin-6-yloxy methyl)pyrrolidine-1-carboxylate 28. Thiazol-4-ylmethyl (+/-)-3-(quinolin-7-yloxymethyl) pyrrolidine-1-carboxylate 29. Thiazol-4-ylmethyl (+/-)-3-(isoquinolin-7-yloxy methyl)pyrrolidine-1-carboxylate 30. Thiazol-4-ylmethyl (+/-)-3-(4-chloro-3-{trifluoro methyl}phenoxymethyl)pyrrolidine-1-carboxylate 31. Thiazol-4-ylmethyl (+/-)-3-(5-fluoronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate 32. Thiazol-2-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl] piperidine-1-carboxylate 33. Thiazol-2-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl] piperidine-1-carboxylate 34. Thiazol-2-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl] piperidine-1-carboxylate 35. Thiazol-2-ylmethyl 4-[2-(2,5-dichlorophenoxy)ethyl] piperidine-1-carboxylate 18 36. Thiazol-2-ylmethyl 4-[2-(3,4-dichlorophenoxy)ethyl] piperidine-1-carboxylate 37. Thiazol-2-ylmethyl 4-[2-(3,5-dichlorophenoxy)ethyl] piperidine-1-carboxylate 38. Thiazol-2-ylmethyl 4-[2-(4-cyclopentylphenoxy) ethyl]piperidine-1-carboxylate 39. Thiazol-2-ylmethyl 4-[2-(2-{benzoxazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate 40. Thiazol-2-ylmethyl 4-[2-(4-{benzyloxy}phenoxy)ethyl] piperidine-1-carboxylate 41. Thiazol-2-ylmethyl 4-[2-(4-{carbamoylmethyl}phenoxy) ethyl]piperidine-1-carboxylate 42. Thiazol-2-ylmethyl 4-[2-(quinolin-7-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 43. Thiazol-2-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 44. Thiazol-2-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate 45. Thiazol-2-ylmethyl 4-[2-(biphenyl-2-yloxy)ethyl] piperidine-1-carboxylate 46. Thiazol-2-ylmethyl 4-[2-(2-isopropyl-5-methyl phenoxy)ethyl]piperidine-1-carboxylate 47. Thiazol-2-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-1-carboxylate 48. Thiazol-2-ylmethyl 4-{2-[4-(1,1,3,3-tetramethyl butyl)phenoxy]ethyl}piperidine-1-carboxylate 49. Thiazol-2-ylmethyl 4-[2-(4-benzylphenoxy)ethyl] piperidine-1-carboxylate 50. Thiazol-2-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 19 51. Thiazol-2-ylmethyl 4-[2-(4-carbamoylphenoxy)ethyl] piperidine-l-carboxylate 52. Thiazol-2-ylmethyl 4-[2-(3-cyanophenoxy)ethyl] piperidine-1-carboxylate 53. Thiazol-2-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate 54. Thiazol-2-ylmethyl 4-[2-(2-benzylphenoxy)ethyl] piperidine-1-carboxylate 55. Thiazol-2-ylmethyl 4-[2-(8-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 56. Thiazol-2-ylmethyl 4-[2-(3-{methoxycarbonyl}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 57. Thiazol-2-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl] piperidine-1-carboxylate 58. Thiazol-2-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 59. Thiazol-2-ylmethyl 4-[2-(4-hexyloxyphenoxy)ethyl] piperidine-1-carboxylate 60. Thiazol-2-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl] piperidine-1-carboxylate 61. Thiazol-2-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 62. Thiazol-2-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-1-carboxylate 63. Thiazol-2-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 64. Thiazol-2-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate 65. Thiazol-2-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 20 66. Thiazol-2-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate 67. Thiazol-2-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy) ethyl]piperidine-1-carboxylate 68. Thiazol-2-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate 69. Thiazol-2-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl] piperidine-l-carboxylate 70. Thiazol-2-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl] piperidine-1-carboxylate 71. Thiazol-2-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 72. Thiazol-2-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 73. Thiazol-2-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate 74. Thiazol-2-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate 75. Thiazol-2-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate 76. Thiazol-2-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-1-carboxylate 77. Thiazol-4-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl] piperidine-1-carboxylate 78. Thiazol-4-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl] piperidine-1-carboxylate 79. Thiazol-4-ylmethyl 4-[2-(naphth-1-yloxy)ethyl] piperidine-1-carboxylate 80. Thiazol-4-ylmethyl 4-[2-(3-{dimethylamino}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 21 81. Thiazol-4-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-l-carboxylate 82. Thiazol-4-ylmethyl 4-[2-(4-benzylphenoxy)ethyl] piperidine-1-carboxylate 83. Thiazol-4-ylmethyl 4-[2-(2-ethoxyphenoxy)ethyl] piperidine-1-carboxylate 84. Thiazol-4-ylmethyl 4-{2-[4-(1-methyl-1-phenylethyl) phenoxy]ethyl}piperidine-1-carboxylate 85. Thiazol-4-ylmethyl 4-[2-(4-phenoxyphenoxy)ethyl] piperidine-1-carboxylate 86. Thiazol-4-ylmethyl 4-[2-(2-bromo-4-fluorophenoxy) ethyl]piperidine-1-carboxylate 87. Thiazol-4-ylmethyl 4-[2-(2-benzylphenoxy)ethyl] piperidine-1-carboxylate 88. Thiazol-4-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl] piperidine-1-carboxylate 89. Thiazol-4-ylmethyl 4-[2-(4-{hexyloxy}phenoxy)ethyl] piperidine-1-carboxylate 90. Thiazol-4-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl] piperidine-1-carboxylate 91. Thiazol-4-ylmethyl 4-[2-(4-chloro-5-isopropyl-2 methylphenoxy)ethyl]piperidine-1-carboxylate 92. Thiazol-4-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-1-carboxylate 93. Thiazol-4-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 94. Thiazol-4-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate 95. Thiazol-4-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate 22 96. Thiazol-4-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy) ethyl]piperidine-1-carboxylate 97. Thiazol-4-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate 98. Thiazol-4-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl] piperidine-l-carboxylate 99. Thiazol-4-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl] piperidine-1-carboxylate 100. Thiazol-4-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-1-carboxylate 101. Thiazol-4-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate 102. Thiazol-4-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate 103. Thiazol-4-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 104. Thiazol-4-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-1-carboxylate 105. Thiazol-2-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoro acetate 106. Thiazol-2-ylmethyl 4-[2-(naphth-2-yloxy)ethyl] piperidine-1-carboxylate 107. Thiazol-2-ylmethyl 4-[2-(naphth-1-yloxy)ethyl] piperidine-1-carboxylate 108. Thiazol-2-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate 109. Thiazol-4-ylmethyl 4-[2-(2-cyclopentylphenoxy) ethyl]piperidine-1-carboxylate 23 110. Thiazol-4-ylmethyl 4-[2-(2-benzyloxyphenoxy)ethyl] piperidine-l-carboxylate 111. Thiazol-4-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 112. Thiazol-4-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl] piperidine-1-carboxylate and its trifluoroacetate 113. Thiazol-4-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 114. Thiazol-4-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 115. Thiazol-4-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl] piperidine-1-carboxylate 116. Thiazol-4-ylmethyl 4-[2-(4-cyclopentylphenoxy) ethyl]piperidine-1-carboxylate 117. Thiazol-4-ylmethyl 4-[2-(2-{benzoxazol-2-yl} phenoxy)ethyl]piperidine-1-carboxylate 118. Thiazol-4-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate 119. Thiazol-4-ylmethyl 4-{2-[4-(1,1,3,3-tetramethyl butyl)phenoxy]ethyl}piperidine-1-carboxylate 120. Thiazol-4-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 121. Thiazol-4-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate 122. Thiazol-4-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoroacetate 123. Thiazol-4-ylmethyl 4-[2-(2-methylquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 24 124. Thiazol-4-ylmethyl 4-[2-(3-cyanophenoxy)ethyl] piperidine-l-carboxylate 125. Thiazol-5-ylmethyl 4-(2-phenoxyethyl)piperidine-1 carboxylate 126. Thiazol-5-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl] piperidine-1-carboxylate 127. Thiazol-5-ylmethyl 4-[2-(4-carbamoylphenoxy)ethyl] piperidine-1-carboxylate 128. Thiazol-5-ylmethyl 4-[2-(4-fluorophenoxy)ethyl] piperidine-1-carboxylate 129. Thiazol-5-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl] piperidine-1-carboxylate 130. Thiazol-5-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoroacetate 131. Thiazol-5-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl] piperidine-1-carboxylate 132. Thiazol-5-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl] piperidine-1-carboxylate 133. Thiazol-5-ylmethyl 4-[2-(2,5-dichlorophenoxy)ethyl] piperidine-1-carboxylate 134. Thiazol-5-ylmethyl 4-[2-(3,5-dichlorophenoxy)ethyl] piperidine-1-carboxylate 135. Thiazol-5-ylmethyl 4-[2-(4-cyclopentylphenoxy) ethyl]piperidine-1-carboxylate 136. Thiazol-5-ylmethyl 4-[2-(naphth-2-yloxy)ethyl] piperidine-1-carboxylate 137. Thiazol-5-ylmethyl 4-[2-(naphth-1-yloxy)ethyl] piperidine-1-carboxylate 25 138. Thiazol-5-ylmethyl 4-[2-(2-methylquinolin-8-yloxy) ethyl]piperidine-1-carboxylate 139. Thiazol-5-ylmethyl 4-[2-(2-{benzoxazol-2-yl} phenoxy)ethyl]piperidine-l-carboxylate 140. Thiazol-5-ylmethyl 4-[2-(4-{benzyloxy}phenoxy)ethyl] piperidine-1-carboxylate 141. Thiazol-5-ylmethyl 4-[2-(4-sulphamoylphenoxy)ethyl] piperidine-1-carboxylate 142. Thiazol-5-ylmethyl 4-[2-(isoquinolin-5-yloxy)ethyl] piperidine-1-carboxylate 143. Thiazol-5-ylmethyl 4-[2-(4-{carbamoylmethyl} phenoxy)ethyl]piperidine-1-carboxylate 144. Thiazol-5-ylmethyl 4-[2-(quinolin-7-yloxy)ethyl] piperidine-1-carboxylate 145. Thiazol-5-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl] piperidine-1-carboxylate 146. Thiazol-5-ylmethyl 4-[2-(quinolin-8-yloxy)ethyl] piperidine-1-carboxylate 147. Thiazol-5-ylmethyl 4-[2-(3-{dimethylamino}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 148. Thiazol-5-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate 149. Thiazol-5-ylmethyl 4-[2-(biphenyl-2-yloxy)ethyl] piperidine-1-carboxylate 150. Thiazol-5-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl] piperidine-1-carboxylate 151. Thiazol-5-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-1-carboxylate 152. Thiazol-5-ylmethyl 4-[2-(4-benzylphenoxy)ethyl] piperidine-1-carboxylate 26 153. Thiazol-5-ylmethyl 4-[2-(2-ethoxyphenoxy)ethyl] piperidine-1-carboxylate 154. Thiazol-5-ylmethyl 4-[2-(2-cyclopentylphenoxy)ethyl] piperidine-1-carboxylate 155. Thiazol-5-ylmethyl 4-{2-[4-(1-methyl-1-phenylethyl) phenoxy]ethyl}piperidine-l-carboxylate 156. Thiazol-5-ylmethyl 4-[2-(4-phenoxyphenoxy)ethyl] piperidine-1-carboxylate 157. Thiazol-5-ylmethyl 4-[2-(2-bromo-4-fluorophenoxy) ethyl]piperidine-1-carboxylate 158. Thiazol-5-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate 159. Thiazol-5-ylmethyl 4-[2-(3-cyanophenoxy)ethyl] piperidine-1-carboxylate 160. Thiazol-5-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate 161. Thiazol-5-ylmethyl 4-[2-(2-benzylphenoxy)ethyl] piperidine-1-carboxylate 162. Thiazol-5-ylmethyl 4-[2-(2-{benzyloxy}phenoxy)ethyl] piperidine-1-carboxylate 163. Thiazol-5-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate 164. Thiazol-5-ylmethyl 4-[2-(3-{methoxycarbonyl}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 165. Thiazol-5-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl] piperidine-1-carboxylate 166. Thiazol-5-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-1-carboxylate 167. Thiazol-5-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl] piperidine-1-carboxylate 27 168. Thiazol-5-ylmethyl 4-[2-(4-{hexyloxy}phenoxy)ethyl] piperidine-1-carboxylate 169. Thiazol-5-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl] piperidine-1-carboxylate 170. Thiazol-5-ylmethyl 4-[2-(4-chloro-5-isopropyl-2 methylphenoxy)ethyl]piperidine-l-carboxylate 171. Thiazol-5-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate 172. Thiazol-5-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl] piperidine-1-carboxylate 173. Thiazol-5-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-1-carboxylate 174. Thiazol-5-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate 175. Thiazol-5-ylmethyl 4-[2-(4-{difluoromethoxy}phenoxy) ethyl]piperidine-1-carboxylate 176. Thiazol-5-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate 177. Thiazol-5-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy) ethyl]piperidine-1-carboxylate 178. Thiazol-5-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate 179. Thiazol-5-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate 180. Thiazol-5-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-1-carboxylate 181. Thiazol-5-ylmethyl 4-[2-(2-carbamoyl-4-chloro phenoxy)ethyl]piperidine-1-carboxylate 182. Thiazol-5-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 28 183. Thiazol-5-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate 184. Thiazol-5-ylmethyl 4-[2-(4-{methanesulphonyl} phenoxy)ethyl]piperidine-l-carboxylate 185. Thiazol-5-ylmethyl 4-[2-(5-acetylamino-2-propyl phenoxy)ethyl]piperidine-1-carboxylate 186. Thiazol-5-ylmethyl 4-[2-(1H-indol-6-yloxy)ethyl] piperidine-1-carboxylate 187. Thiazol-5-ylmethyl 4-{2-[4-fluoro-2-(1H-pyrazol-3 yl)phenoxy]ethyl}piperidine-1-carboxylate 188. Thiazol-5-ylmethyl 4-[2-(4-cyano-2-fluorophenoxy) ethyl]piperidine-1-carboxylate 189. Thiazol-5-ylmethyl 4-[2-(2-isopropyl-5-methyl phenoxy)ethyl]piperidine-1-carboxylate 190. Thiazol-5-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate 191. Thiazol-5-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate 192. Thiazol-5-ylmethyl 4-{2-[4-(2-oxopyrrolidin-1-yl) phenoxy]ethyl}piperidine-1-carboxylate 193. Thiazol-5-ylmethyl 4-[2-(3-{tetrazol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate 194. Thiazol-2-ylmethyl (R)-3-(naphth-2-yloxymethyl) pyrrolidine-1-carboxylate (enantiomer I) 195. Thiazol-2-ylmethyl (S)-3-(naphth-2-yloxymethyl) pyrrolidine-1-carboxylate (enantiomer II) 196. Thiazol-2-ylmethyl (+/-)-3-(5-chloronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate 197. Thiazol-2-ylmethyl (+/-)-3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine-1-carboxylate 29 198. 3-Carbamoylisoxazol-5-ylmethyl 4-[2-(4-fluoro phenoxy)ethyl]piperidine-l-carboxylate 199. 3-Carbamoylisoxazol-5-ylmethyl 4-[2-(4-{trifluoro methoxy}phenoxy)ethyl]piperidine-1-carboxylate 200. 3-Carbamoylisoxazol-5-ylmethyl (-)-(R)-3-(naphth-2 yloxymethyl)pyrrolidine-1-carboxylate (enantiomer I) 201. 3-Carbamoylisoxazol-5-ylmethyl (+/-)-3-(6-methoxy naphth-2-yloxymethyl)pyrrolidine-1-carboxylate 202. 3-Carbamoylisoxazol-5-ylmethyl (+) - (S) -3- (naphth-2 yloxymethyl)pyrrolidine-1-carboxylate (enantiomer II). The compounds of general formulae (I), (Ii) and (Iii) can comprise one or more asymmetric carbon atoms. They can exist in the form of enantiomers or diastereoisomers. These enantiomers and diastereoisomers and their mixtures, including the racemic mixtures, come within the invention. The compounds of formulae (I), (Ii) and (Iii) can exist in the form of bases or of addition salts with acids. Such addition salts come within the invention. These salts are advantageously prepared with pharmaceutically acceptable acids but the salts of other acids, for example of use in the purification or the isolation of the compounds of formulae (I), (Ii) and (Iii), also come within the invention. The compounds of formulae (I), (Ii) and (Iii) and/or salts thereof may form solvates or hydrates and the invention includes all such solvates and hydrates. The term < hydrates > and < solvates > mean that the compounds of formulae (I), (Ii) and (Iii) according to the invention can be combined or associated with one or more water or solvent 30 molecules. This is only a chemical characteristic of such compounds, which can be applied for all organic compounds of this type. In the context of the invention: - The term "comprising" as used in this specification means "consisting at least in part of". When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner. - Ct-z, where t and z can take the values from 1 to 8, is understood to mean a carbon-comprising chain which can have from t to z carbon atoms, for example C 1

-

3 is understood to mean a carbon-comprising chain which can have from 1 to 3 carbon atoms; - alkyl is understood to mean a saturated and linear or branched aliphatic group; for example, a C 1

-

6 -alkyl group represents a linear or branched carbon-comprising chain of 1 to 6 carbon atoms, more particularly a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or hexyl; - alkylene is understood to mean a saturated and linear or branched divalent alkyl group; for example, a Ci_ 3 -alkylene group represents a linear or branched divalent carbon comprising chain of 1 to 3 carbon atoms, more particularly a methylene, ethylene, 1-methylethylene or propylene; - cycloalkyl is understood to mean a cyclic alkyl group; for example, a C 3

-

7 -cycloalkyl group represents a cyclic carbon comprising group of 3 to 7 carbon atoms, more particularly a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; - alkoxy is understood to mean an -0-alkyl group comprising a saturated and linear or branched aliphatic chain; 31 - thioalkyl is understood to mean an -S-alkyl group comprising a saturated and linear or branched aliphatic chain; - haloalkyl is understood to mean an alkyl group, one or more hydrogen atoms of which have been replaced by a halogen atom; - haloalkoxy is understood to mean an alkoxy group, one or more hydrogen atoms of which have been replaced by a halogen atom; - halothioalkyl is understood to mean a thioalkyl group, one or more hydrogen atoms of which have been replaced by a halogen atom; - halogen atom is understood to mean a fluorine, a chlorine, a bromine or an iodine; - TFA is understood to mean trifluoroacetic acid; - ACN is understood to mean acetonitrile. Within the meaning of the present invention, it should be noted that the terms "ranging from ... to ... " and "between ... and mean that the limits are also considered. The term < preventing >, as used herein, means reducing the risk of onset or slowing the occurrence of a given phenomenom, namely in the present invention, a pathology in which endogenous cannabinoids and/or other substrates metabolized by the enzyme FAAH are involved such as the pathologies as defined below. Another subject-matter of the invention is targeted at a process for the preparation of the compounds of formula (I) according to the invention, comprising reacting an amine derivative, a compound of following general formula (II): R2 NH R, -A , (11) 32 in which R 1 , R 2 , A, n and m are as defined in the formula (I) defined above, with a carbonate of following general formula (III): z0 O R 4 (IlI) in which Z represents a hydrogen atom or a nitro group and R 3 and R 4 are as defined in the general formula (I) defined above, in the presence of a base, such as triethylamine, pyridine, N, N-dimethylaminopyridine or N, N-diisopropyl ethylamine, in an organic solvent, such as toluene, acetonitrile or dichloroethane, at a temperature between ambient temperature and the reflux temperature of the solvent. In addition, the compounds of the invention can be prepared according to different methods illustrated by the following schemes and using the intermediate compounds described. If appropriate, a compound of formula (II) can be protected, in particular at its amine functional group, according to methods well known to a person skilled in the art. Mention may be made, as examples of protective groups and also of protecting and deprotecting methods, of the work "Protective Groups in Organic Synthesis", Green et al., 2 d Edition (John Wiley & Sons, Inc., New York). A preparation process employing a protected compound of formula (II) is, for example, described in the following Scheme 1. As regards more particularly the compounds of general formula (I) in which A more particularly represents an oxygen atom or an -O-Ci- 6 -alkylene group, they can also be prepared according to the procedure described in the following Scheme 1.

33 Scheme 1 z 0

R

3 R 1) R 1 OH or R 1 X R O O R H-11sG-" NPG (IV) (IVa) 0 NH() 2) deprotection R1 (Ila) (llb) (alternative form)

R

1 OH or R 1 X deprotection (IV) (IVa) RR HOsR \<NH 01 HOs G 4 N4 R3 R4 (llc) (Ia) This preparation method (Scheme 1) consists in reacting, in a first step, an alcohol of general formula (IIa), in which R 2 , m and n are as defined in the general formula (I) as defined above, G represents a portion of the group A as defined in the general formula (I), namely either a covalent bond or the C 1

-

6 alkylene portion of the -O-Ci- 6 -alkylene group, and PG represents a protective group, such as a Boc (tert butyloxycarbonyl), a Cbz (benzyloxycarbonyl), a benzyl or a benzhydryl; - either with an alcohol derivative of general formula (IV), in which Ri is as defined above, using the Mitsunobu reaction conditions (Synthesis, 1981, 1-28), - or with a halogenated derivative of general formula (IVa), in which Ri is as defined above and X represents a fluorine, chlorine, bromine or iodine atom, using aromatic or heteroaromatic nucleophilic substitution reactions or Buchwald O-arylation or O-heteroarylation reactions, for example using a palladium or copper catalyst; followed by a deprotection reaction, for example in the presence of trifluoroacetic acid or of a solution of 34 hydrochloric acid in isopropanol or dioxane, to result in the amine of general formula (IIb) in which G, R 2 , m and n are as defined in the amine of formula (IIa) above and Ri is as defined in the general formula (I) as defined above. An alternative to the Mitsunobu reaction consists in reacting an alcohol derivative of general formula (IV) with a compound said to be of general formula (IIe) and deriving from the activation by a tosylate group of the alcohol functional group of a compound of general formula (IIa) . The derivative of general formula (IIb) thus obtained is subsequently converted to the compound of general formula (I) according to a condensation reaction with a carbonate of general formula (III) as defined above, under the conditions described above. An alternative form of producing the compounds of general formula (I) (Scheme 1) in which A more particularly represents an oxygen atom or an -O-Ci- 6 -alkylene group consists in deprotecting an alcohol of general formula (IIa) as defined above, according to a deprotection reaction as defined above, in order to obtain an aminoalcohol of general formula (IIc), and in then reacting this aminoalcohol of general formula (IIc) in which R 2 , m and n are as defined in the general formula (I) defined above and G represents a portion of the group A as defined in the general formula (I), namely either a covalent bond or the C 1 6 -alkylene portion of the -0-C 1

-

6 alkylene group, with a carbonate of general formula (III) as defined above under the conditions described above, to result in the carbamate derivative of general formula (Ia) in which

R

2 , R 3 , R 4 , m and n are as defined in the general formula (I) defined above and G represents a portion of the group A as defined in the general formula (I), namely either a covalent bond or the C 1

-

6 -alkylene portion of the -O-Ci- 6 -alkylene group. The carbamate derivative (Ia) thus obtained is subsequently converted to the compound of general formula (I) by the action 35 of an alcohol of general formula RiOH (IV) as defined above by using the Mitsunobu reaction conditions or by the action of a halogenated derivative of general formula RiX (IVa) as defined above by using aromatic or heteroaromatic nucleophilic substitution reactions or Buchwald O-arylation or 0 heteroarylation reactions, for example using a palladium or copper catalyst. As regards more particularly the compounds of general formula (I) in which Ri represents an R 5 group substituted in particular by an R 6 group of C 1

-

6 -alkyl, C 3

-

7 -cycloalkyl or C 3

-

7 cycloalkyl-Ci_ 3 -alkylene type or by an R 7 group as defined in the general formula (I) defined above, they can also be prepared according to the procedure described in the following Scheme 2. Scheme 2 z 0 O R R 5-A R 5- A (lid) (Ib) 4 Suzuki or Stille or Negishi (I) Thus, the first stage consists in reacting an amine of general formula (IId), in which A, R 2 , R 5 , m and n are as defined in the general formula (I) defined above and Ui represents a chlorine, bromine or iodine atom or a triflate group, with a carbonate of general formula (III) as defined above under the conditions described above, to result in the carbamate 36 derivative of general formula (Ib) in which A, R 2 , R 3 , R 4 , R 5 , m and n are as defined in the general formula (I) defined above and Ui is as defined above. The coupling reaction catalysed by means of a transition metal, such as palladium(O), is subsequently carried out on the key intermediate of general formula (Ib) as defined above, Ui being in the position where it is desired to introduce the R 6 or R 7 group (Scheme 2): - either by a reaction of Suzuki type, for example using an alkyl-, cycloalkyl-, aryl- or heteroarylboronic acid, - or according to a reaction of Stille type, for example using a trialkylaryltin or trialkylheteroaryltin derivative, - or by a reaction of Negishi type, for example using an alkyl-, cycloalkyl-, aryl- or heteroarylzinc halide derivative. Alternatively, the other compounds of general formulae (II), (IIa), (IIb), (IIc), (IId), (III), (IV) and (IVa) and the other reactants are commercially available or are described in the literature or else can be prepared according to methods which are described therein or which are known to a person skilled in the art. Described are compounds of general formula (Ia): R 0 HO G N4O R3 (la) 4 in which R 2 , R 3 , R 4 , m and n are as defined in the general formula (I) and G represents a portion of the group A as defined in the general formula (I), namely either a covalent bond or the C 1

-

6 -alkylene portion of the -O-Ci- 6 -alkylene group. Mention may be made, among these compounds, of: e thiazol-2-ylmethyl 4-(2-hydroxyethyl)piperidine-1- 37 carboxylate thiazol-4-ylmethyl 3-(hydroxymethyl)pyrrolidine-1 carboxylate. Described are compounds of general formula (II): R2 2m NH R-A (II) in which A, R 1 , R 2 , m and n are as defined in the general formula (I). Mention may be made, among these compounds, of: * 4-[2-(4-chloronaphth-1-yloxy)ethylipiperidine e 3-(6-methoxynaphth-2-yloxymethyl)pyrrolidine e 3'-(pyrrolidin-3-ylmethoxy)biphenyl-3-carbonitrile e 3-(5-chloronaphth-2-yloxymethyl)pyrrolidine e 3-(3-{trifluoromethoxy}phenoxymethyl)pyrrolidine e 3-[4-(1-methyl-1-phenylethyl)phenoxymethyl]pyrrolidine * 7-(pyrrolidin-3-ylmethoxy)quinoline e 3-(pyrrolidin-3-ylmethoxy)quinoline e 3-(4-chloro-3-{trifluoromethyl}phenoxymethyl)pyrrolidine * 7-(pyrrolidin-3-ylmethoxy)isoquinoline e 3-(5-fluoronaphth-2-yloxymethyl)pyrrolidine e 3-(4'-fluorobiphenyl-4-yloxymethyl)pyrrolidine The following examples illustrate the preparation of some compounds of the invention. These examples are not limiting and serve only to illustrate the invention. The NMR spectra and/or the LC-MS (Liquid Chromatography-Mass Spectroscopy) confirm the structures and the purities of the compounds obtained.

38 M.p.( 0 C) represents the melting point in degrees Celsius. Rf indicates the retention time obtained by TLC (Thin Layer Chromatography) analysis. The numbers shown in brackets in the titles of the examples correspond to those in the 1st column of the tables below. The IUPAC (International Union of Pure and Applied Chemistry) nomenclature was used in the naming of the compounds in the examples below. Example 1 (Compound No. 17) Thiazol-4-ylmethyl 3- (naphth-2-yloxymethyl)pyrrolidine-1 carboxylate S O N O --- N 1.1 Thiazol-4-ylmethyl 3-(hydroxymethyl)pyrrolidine-1 carboxylate A solution of 3.00 g (10.70 mmol) of thiazol-4-ylmethyl 4 nitrophenyl carbonate in 20 ml of dichloromethane is added at ambient temperature, via a dropping funnel, to a solution of 1.13 g (11.24 mmol) of pyrrolidin-3-ylmethanol (commercial) in 20 ml of methanol. The solution is stirred for 15 hours. Water is subsequently added to the reaction medium. After extraction of the aqueous phase with dichloromethane, the organic phases are successively washed with a 1M aqueous sodium hydroxide solution and then with a saturated aqueous sodium chloride solution. After having dried the organic phases over sodium sulphate, the mixture is filtered and the filtrate is evaporated to dryness. 0.56 g of the desired product is thus 39 obtained in the form of an oil after purification on a column of silica gel, elution being carried out with a dichloromethane/methanol (97/3 to 95/5) mixture. 1.2 Thiazol-4-ylmethyl 3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate 0.25 g (1.03 mmol) of thiazol-4-ylmethyl 3 (hydroxymethyl)pyrrolidine-1-carboxylate is dissolved in 8 ml of toluene. 0.35 g (1.34 mmol) of triphenylphosphine and 0.16 g (1.13 mmol) of naphth-2-ol are added and then the medium is cooled to 0 0 C for slow addition of a solution of 0.27 g (1.34 mmol) of diisopropyl azodicarboxylate in 2 ml of toluene. The medium is stirred at ambient temperature for 14 hours. The residue obtained is taken up in water and extracted twice with dichloromethane. The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated under vacuum. The residue is purified by chromatography on silica gel, elution being carried out with a 99/1 to 98/2 mixture of dichloromethane and methanol. 0.15 g of the expected product is obtained in the form of a powder. M.p. ( 0 C) : 90-92 LC-MS: M+H = 369 'H NMR (d 6 -DMSO) 5 (ppm) : 9.10 (s, 1H) ; 7.85 (m, 3H) ; 7.70 (m, 1H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 5.20 (s, 2H); 4.10 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 3.30 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) Example 2 (Compound No. 22) Thiazol-4-ylmethyl 3- (4' -fluorobiphenyl-4-yloxymethyl) pyrrolidine-1-carboxylate F O N O N O0 40 2.1 tert-Butyl 3-(4'-fluorobiphenyl-4-yloxymethyl)pyrrolidine 1-carboxylate The procedure is the same as for Example 1 (Stage 1.2) starting from 1.50 g (7.45 mmol) of tert-butyl 3 (hydroxymethyl)pyrrolidine-1-carboxylate (commercial), 2.15 g (11.18 mmol) of 4'-fluorobiphenyl-4-ol, 2.93 g (11.18 mmol) of triphenylphosphine and 2.26 g (11.18 mmol) of diisopropyl azodicarboxylate. After purification by chromatography on a column of silica gel, elution being carried out with dichloromethane, 1.55 g of the expected product are obtained in the form of an oil. 2.2 3-(4'-Fluorobiphenyl-4-yloxymethyl)pyrrolidine 1.55 g (4.17 mmol) of tert-butyl 3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine-1-carboxylate are dissolved in 40 ml of dichloromethane and then, at 0 0 C, 6.00 ml (80.77 mmol) of trifluoroacetic acid are subsequently added. After stirring at ambient temperature for two hours, the mixture is concentrated to dryness and then the residue is taken up in water and dichloromethane. A saturated sodium hydrogencarbonate solution is added and then the aqueous phase is extracted with dichloromethane. The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate, filtered and concentrated under vacuum. 0.98 g of product is obtained in the form of an oil, used as is in the following stage. 2.3 Thiazol-4-ylmethyl 3-(4'-fluorobiphenyl-4-yloxymethyl) pyrrolidine-1-carboxylate 0.30 g (1.07 mmol) of thiazol-4-ylmethyl 4-nitrophenyl carbonate, 0.34 g (1.28 mmol) of 3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine, 0.20 g (1.61 mmol) of NN diisopropylethylamine and 0.01 g (0.11 mmol) of 41 dimethylaminopyridine are dissolved in 10 ml of 1,2 dichloroethane. The mixture is stirred at 70 0 C for 4 hours. After returning to ambient temperature, water is added to the reaction medium. After extraction of the aqueous phase with dichloromethane, the organic phases are successively washed three times with a 1M aqueous sodium hydroxide solution and then twice with a saturated aqueous ammonium chloride solution. After having dried the organic phases over sodium sulphate, they are filtered and the filtrate is evaporated to dryness. After purification by chromatography on a column of silica gel, elution being carried out with dichloromethane and methanol (98/2), 0.16 g of the expected product is obtained in the form of a powder. M.p. ( 0 C): 115-117 LC-MS: M+H = 413 'H NMR (d 6 -DMSO) 5 (ppm): 9.10 (s, 1H) ; 7.70 (m, 3H) ; 7.60 (d, 2H); 7.30 (m, 2H); 7.05 (m, 2H); 5.20 (s, 2H); 4.05 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.35 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) Example 3 (Compound No. 200) 3-Carbamoylisoxazol-5-ylmethyl (-) - (R) -3- (naphth-2-yloxy methyl) pyrrolidine-1-carboxylate e- Chiral N oo.N 0-N 3.1 tert-Butyl (R)-3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate The procedure is the same as for Example 1 (Stage 1.2) starting from 2.00 g (9.94 mmol) of tert-butyl (R)-3 (hydroxymethyl)pyrrolidine-1-carboxylate (commercial), 2.00 g 42 (13.91 mmol) of naphth-2-ol, 3.90 g (14.91 mmol) of triphenylphosphine and 3.01 g (14.91 mmol) of diisopropyl azodicarboxylate. 1.75 g of product are obtained in the form of an oil after purification on a column of silica gel, elution being carried out with dichloromethane. 3.2 (R)-3-(naphth-2-yloxymethyl)pyrrolidine The procedure is the same as for Example 2 (Stage 2.2) starting from 1.75 g (5.34 mmol) of tert-butyl (R)-3-(naphth 2-yloxymethyl)pyrrolidine-1-carboxylate and 5.00 ml (67.31 mmol) of trifluoroacetic acid. 1.20 g of product are obtained in the form of an oil. 3.3 3-Carbamoylisoxazol-5-ylmethyl 4-nitrophenyl carbonate 2.84 g (14.07 mmol) of 4-nitrophenyl chloroformate are added in small portions to a solution, cooled to approximately 0 0 C, of 2.00 g (14.07 mmol) of 3-carbamoylisoxazol-5-ylmethanol, 1.71 ml (21.11 mmol) of pyridine and 0.17 g (1.41 mmol) of N,N-dimethylaminopyridine in 15 ml of dichloromethane. The medium is kept stirred at 0 0 C for 1 hour and then at ambient temperature for 1 hour. The precipitate formed is filtered off and then copiously rinsed with diisopropyl ether. After drying under vacuum at approximately 60 0 C, 3.12 g (72%) of the expected product are obtained in the form of a white solid used as is in the following stage. M.p.( 0 C): 143-145 H NMR (d 6 -DMSO, 400 MHz) D (ppm) : 8.40 (d, 2H) ; 8.25 (broad s, 1H); 7.90 (broad s, 1H); 7.65 (d, 2H); 7.0 (s, 1H); 5.50 (s, 2H). 3.4 3-Carbamoylisoxazol-5-ylmethyl (-)-(R)-3-(naphth-2-yloxy methyl)pyrrolidine-1-carboxylate 0.21 g (0.92 mmol) of (R)-3-(naphth-2-yloxymethyl)pyrrolidine is dissolved in 3.80 ml of dichloromethane and then 0.31 g 43 (1.01 mmol) of 3-carbamoylisoxazol-5-ylmethyl 4-nitrophenyl carbonate and 0.15 ml (1.38 mmol) of N-methylmorpholine are added. The mixture is stirred at ambient temperature for 20 hours and then water is added to the reaction medium. After extraction of the aqueous phase with dichloromethane, the organic phases are successively washed three times with a 1M aqueous sodium hydroxide solution and then twice with a saturated aqueous ammonium chloride solution. After having dried the organic phases over sodium sulphate, they are filtered and the filtrate is evaporated to dryness. 0.14 g of the desired product is thus obtained in the form of a white solid after purification on a column of silica gel, elution being carried out with a dichloromethane/methanol mixture, and then taken up in isopropyl ether. M.p.( 0 C): 138-140 LC-MS: M+H = 396 'H NMR (d 6 -DMSO) 5 (ppm) : 8.15 (broad s, 1H) ; 7.80 (m, 4H) ; 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 6.80 (s, 1H); 5.30 (s, 2H); 4.10 (m, 2H); 3.65 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) [av] 21c -7.917" (c = 0.312; DMSO, 589 nm) Example 4 (Compound No. 202) 3-Carbamoylisoxazol-5-ylmethyl (+) - (S) -3- (naphth-2-yloxy methyl) pyrrolidine-1-carboxylate 4.1 tert-Butyl (S)-3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate The procedure is the same as for Example 1 (Stage 1.2) starting from 2.00 g (9.94 mmol) of tert-butyl (S)-3 (hydroxymethyl)pyrrolidine-1-carboxylate (commercial), 2.00 g (13.91 mmol) of naphth-2-ol, 3.90 g (14.91 mmol) of triphenylphosphine and 3.01 g (14.91 mmol) of diisopropyl azodicarboxylate. 2.80 g of product are obtained in the form 44 of an oil after purification on a column of silica gel, elution being carried out with dichloromethane. 4.2 (S)-3-(Naphth-2-yloxymethyl)pyrrolidine The procedure is the same as for Example 2 (Stage 2.2) starting from 1.75 g (5.34 mmol) of tert-butyl (S)-3-(naphth 2-yloxymethyl)pyrrolidine-1-carboxylate and 5.00 ml (67.31 mmol) of trifluoroacetic acid. The product is obtained in the form of an oil after purification on a column of silica gel, elution being carried out with a dichloromethane/methanol/aqueous ammonia (90/9/1) mixture. 4.3 3-Carbamoylisoxazol-5-ylmethyl (+)-(S)-3-(naphth-2-yloxy methyl)pyrrolidine-1-carboxylate The procedure is the same as for Example 3 (Stage 3.4) starting from 0.21 g (0.95 mmol) of (S)-3-(naphth-2 yloxymethyl)pyrrolidine, 0.32 g (1.04 mmol) of 3 carbamoylisoxazol-5-ylmethyl 4-nitrophenyl carbonate (Stage 4.3) and 0.16 ml (1.42 mmol) of N-methylmorpholine. 0.21 g of a powder is obtained after purification on a column of silica gel, elution being carried out with a dichloromethane/methanol mixture, and trituration from isopropyl ether. M.p.( 0 C): 139-141 LC-MS: M+H = 396 'H NMR (d 6 -DMSO) 5 (ppm) : 8.15 (broad s, 1H) ; 7.80 (m, 4H) ; 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 6.80 (s, 1H); 5.30 (s, 2H); 4.10 (m, 2H); 3.65 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) [av] 21C +9.9440 (c = 0.036; DMSO, 589 nm) The chemical structures and the physical properties of some compounds according to the invention are illustrated in the following Table 1. In this table, the compounds are in the free base or salt form.

45 * A represents an -O-Ci- 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group.

46 Table 1 0 R3 R2p Base or N Ri m n A* R 2

R

3 R4 salt Ci base 1. 2 2 -OCH 2

CH

2 - H H N F, base 2. 2 2 -OCH 2

CH

2 - H H base 3. 2 2 -OCH 2

CH

2 - H H FF base 4. F 2 2 -OCH 2

CH

2 - H H S Cl Nbase 5. 2 2 -OCH 2

CH

2 - H H S FN base 6. 2 2 -OCH 2

CH

2 - H H Cl z N--\ base 7. 2 2 -OCH 2

CH

2 - H H FF Nbase 8. F 2 2 -OCH 2

CH

2 - H H 47 Base or No R m n A* R 2

R

3 R4 salt 0 Me base 9. | 2 2 -OCH 2

CH

2 - H H N--\ base 10. 2 2 -OCH 2

CH

2 - H H Me base 11. 2 1 -OCH 2 - H H 0 Me base N-\ 12. | 2 1 -OCH 2 - H H Ci base 13. 2 1 -OCH 2 - H H Me base 0 14. 2 2 -OCH 2

CH

2 - H H N base 15. 2 2 -OCH 2

CH

2 - H H N base 16 . C 1 2 -OCH 2 - H H 48 Base or No R m n A* R 2

R

3 R4 salt base 17. 1 2 -OCH 2 - H H F base 18. 2 2 -OCH 2

CH

2 - H H HCl 19. N 2 2 -OCH 2

CH

2 - H H N N HCl 20. 2 2 -OCH 2

CH

2 - H H S NC base 21. 1 2 -OCH 2 - H H F. base 22. 1 2 -OCH 2 - H H base 23. CI 1 2 -OCH 2 - H H F- N \base 24. OF 1 2 -OCH 2 - H H Me Me N base 25. 1 2 -OCH 2 - H H 49 Base or No R m n A* R 2

R

3 R4 salt base 26. 1 2 -OCH 2 - H H N ,+ N N==\ base 27 . 1 2 -OCH 2 - H H N base 28. 1 2 -OCH 2 - H H N base 29. 1 2 -OCH 2 - H H F F base 30. CI 1 2 -OCH 2 - H H NN\base 31- F 1 2 -OCH 2 - H H base Me Me N 32. 2 2 -OCH 2

CH

2 - H H CI base 33. rkcI 2 2 -OCH 2

CH

2 - H HN ci. ci base 34.2 2 -OCH 2

CH

2 - H H N ci base 35. cl2 2 -OCH 2

CH

2 - H H

N

50 Base or No R m n A* R 2

R

3 R4 salt base 36. cl - 2 2 -OCH 2

CH

2 - H H ci base 37. 2 2 -OCH 2

CH

2 - H H N base 38. 2 2 -OCH 2

CH

2 - H H Nitbase 3 2 2 -OCH 2

CH

2 - H H base 40. 2 2 -OCH 2

CH

2 - H H N 00 K/S

H

2 N 0 base 41. 2 2 -OCH 2

CH

2 - H H N

CF

3

CO

2 H 42. 2 2 -OCH 2

CH

2 - H H N CF 3

CO

2 H 43. 2 2 -OCH 2

CH

2 - H H N - K/S NC' base 44. F ' 2 2 -OCH 2

CH

2 - H H base 45. 2 2 -OCH 2

CH

2 - H H N eS Me base 46. M Me 2 2 -OCH 2

CH

2 - H H N Me base 47. F | 2 2 -OCH 2

CH

2 - H H

F

51 Base or No R m n A* R 2

R

3 R4 salt Me Me base Me 48. M 2 2 -OCH 2

CH

2 - H H N e I base 49. 2 2 -OCH 2

CH

2 - H H

CF

3

CO

2 H 50. N 2 2 -OCH 2

CH

2 - H H 0 base 51. H 2 N 2 2 -OCH 2

CH

2 - H H base 52N. 2 2 -OCH 2

CH

2 - H H NC Me M~e base 53. Me I 2 2 -OCH 2

CH

2 - H H Me base 54. 2 2 -OCH 2

CH

2 - H H N Ns 0 Base 55. N 2 2 -OCH 2

CH

2 - H H N base 56. I 2 2 -OCH 2

CH

2 - H H O'Me base 57. 2 2 -OCH 2

CH

2 - H H 0o .

52 Base or No R m n A* R 2

R

3 R4 salt N CF 3

CO

2 H 58. 2 2 -OCH 2

CH

2 - H H N \ ?6H base 59. 2 2 -OCH 2

CH

2 - H H

?

4 H, base 60. 2 2 -OCH 2

CH

2 - H H N N ,CF 3

CO

2 H 61. N 2 2 -OCH 2

CH

2 - H H F F base 62. F F - 2 2 -OCH 2

CH

2 - H H Fl N H base 63. 2 2 -OCH 2

CH

2 - H H Br Base 64. "a 2 2 -OCH 2

CH

2 - H H ci Me

CF

3

CO

2 H 65. 2 2 -OCH 2

CH

2 - H H NC base 66. 2 2 -OCH 2

CH

2 - H H N \ NC base 67. 2 2 -OCH 2

CH

2 - H H N \ base 68. s 2 2 -OCH 2

CH

2 - H H

<\-N

53 Base or No R m n A* R 2

R

3 R4 salt base 69. -- 2 2 -OCH 2

CH

2 - H H N -- , base 70. 2 2 -OCH 2

CH

2 - H H N \ CN

CF

3

CO

2 H 71. 2 2 -OCH 2

CH

2 - H H N

CF

3

CO

2 H 72. 2 2 -OCH 2

CH

2 - H H N ci CN base 73. me-( 2 2 -OCH 2

CH

2 - H H NC base 74. 2 2 -OCH 2

CH

2 - H H N base 75. N 2 2 -OCH 2

CH

2 - H H N base 76. - . 2 2 -OCH 2

CH

2 - H H ci I 77 . M Me 2 2 -OCH2CH2- H H Sbase N \ base 78. c 2 2 -OCH 2

CH

2

-

H H asS base 79. 2 2 -OCH 2

CH

2 - H H S

CF

3

CO

2 H 80. M 2 2 -OCH 2

CH

2 - H H Me~' *Me 54 Base or No R m n A* R 2

R

3 R4 salt base 81. 2 2 -OCH 2

CH

2 - H H F F base 82. 2 2 -OCH 2

CH

2 - H H \base 83. 2 2 -OCH 2

CH

2 - H H asS - base 84. 2 2 -OCH 2

CH

2 - H H Me Me 85. 2 2 -OCH 2

CH

2 - H H Sbase 8base 86. 2 2 -OCH 2

CH

2 - H H base N \ base 87. 2 2 -OCH 2

CH

2 - H H b base 88. 2 2 -OCH 2

CH

2 - H H JS SCbase 92. FF 2 2 -OCH 2

CH

2 - H H base 93. 2 2 -OCH 2

CH

2 - H H S NH 0 55 Base or No R m n A* R 2

R

3 R4 salt 94. CI 2 2 -OCH 2

CH

2 - H H base Br, base 95. 2 2 -OCH 2

CH

2 - H H CN base 96. 2 2 -OCH 2

CH

2 - H H CN base 97. 2 2 -OCH 2

CH

2 - H H JS N S base 98. 2 2 -OCH 2

CH

2 - H H base 99. 2 2 -OCH 2

CH

2 - H H base 100 I 2 2 -OCH 2

CH

2 - H H bS CI Me base 101 S 2 2 -OCH 2

CH

2 - H H LS base 102 2 2 -OCH 2

CH

2 - H H

CN

56 Base or No R m n A* R 2

R

3 R4 salt NO \CF 3

CO

2 H 103 N 2 2 -OCH 2

CH

2 - H H .O-N base 104 2 2 -OCH 2

CH

2 - H H CI

CF

3

CO

2 H 105 2 2 -OCH 2

CH

2 - H H N

H

3 C'Ns

OH

3 base 106 2 2 -OCH 2

CH

2 - H H N--Sb base 107 2 2 -OCH 2

CH

2 - H H N \ base 108 2 2 -OCH 2

CH

2 - H H N-S-as

OH

3 109 2 2 -OCH 2

CH

2 - H H S base base 110 2 2 -OCH 2

CH

2 - H H

CF

3

CO

2 H 111 N 2 2 -OCH 2

CH

2 - H H

CF

3

CO

2 H 112 2 2 -OCH 2

CH

2 - H H 57 Base or No R m n A* R 2

R

3 R4 salt

CF

3

CO

2 H 113 N 2 2 -OCH 2

CH

2 - H H S N/

CH

3

CF

3

CO

2 H 114 -N 2 2 -OCH 2

CH

2 - H H S CN base 115 2 2 -OCH 2

CH

2 - H H base 1176 2 2 -OCH 2

CH

2 - H HS 1186 2 2 -OCH2CH2- H H N-- base M Base 117 y 0 2 2 -OCH 2

CH

2 - H H N base 118 Me2 2 -OCH 2

CH

2 - H H S F ON Me Me base meN CF3CO2H 121 Me 2 2 -OCH 2

CH

2 - H H Me Iem

'CF

3

CO

2 H 121 Me 2 2 -OCH 2

CH

2 - H H 6H, 58 Base or No R m n A* R 2

R

3 R4 salt

CF

3

CO

2 H 123 -N 2 2 -OCH 2

CH

2 - H H Me N \ base 124 2 2 -OCH 2

CH

2 - H H asS ()CN base 125 2 2 -OCH 2

CH

2 - H H base 126 2 2 -OCH 2

CH

2 - H H N \ base 127 0 2 2 -OCH 2

CH

2 - H H base

NH

2 N \base 128 2 2 -OCH 2

CH

2 - H H b Me N base 129 2 2 -OCH 2

CH

2 - H H b Me

CF

3

CO

2 H 130 HOY 2 2 -OCH 2

CH

2 - H H

OH

3 131 2 2 -OCH 2

CH

2 - H H cl Nbase 132 1 2 2 -OCH 2

CH

2 - H H ci N=-\ base 133 CI 2 2 -OCH 2

CH

2

-

H

59 Base or No R m n A* R 2

R

3 R4 salt N \base 134 2 2 -OCH 2

CH

2 - H H CI C base 135 2 2 -OCH 2

CH

2 - H H 136 2 2 -OCH 2

CH

2 - H H N-S base N1\ base 137 2 2 -OCH 2

CH

2 - H H base 138 N CH3 2 2 -OCH 2

CH

2 - H H N base 13 N 2 2 -OCH 2

CH

2 - H H NH base 140 2 2 -OCH 2

CH

2 - H H SO2NH 2N-\ base 141 2 2 -OCH 2

CH

2 - H H N N--\ base 142 2 2 -OCH 2

CH

2 - H H base N-\ 143 2 2 -OCH 2

CH

2 - H H b I; N \-- base 144 2 2 -OCH2CH2- H H N N \base 145 2 2 -OCH2CH2- H H 60 Base or No R m n A* R 2

R

3 R4 salt base 146 2 2 -OCH 2

CH

2 - H H N \CF3CO2H 147 N'Me 2 2 -OCH 2

CH

2 - H H C Me base 148 F 2 2 -OCH 2

CH

2 - H H S CN . N \base 149 2 2 -OCH 2

CH

2 - H H b N base 150 2 2 -OCH 2

CH

2 - H H S base 151 F 2 2 -OCH 2

CH

2 - H H S FF 152 2 2N \base 153 2 2 -OCH 2

CH

2 - H H OC2Hs N \base 153 2 2 -OCH 2

CH

2 - H H S N basee 154 2 2 -OCH 2

CH

2 - H H S Me me base 155 1 1 2 2 -OCH2CH2- H H N \ base 156 2 2 -OCH 2

CH

2 - H H S Br N \base 157 F 2 2 -OCH 2

CH

2 - H H b

F

61 Base or No R m n A* R 2

R

3 R4 salt N \Cbase 159 N 2 2 -OCH 2

CH

2 - H H b NC -N -\ Sbase 159 2 2 -OCH2CH2- H H base 160 Me Me 2 2 -OCH 2

CH

2 - H H Me MeMe base 161 2 2 -OCH 2

CH

2 - H H base N\ 162 0 2 2 -OCH2CH2- H H CN base 163 N 2 2 -OCH2CH2- H H base N\ 164 | 2 2 -OCH 2

CH

2 - H H S 0 O N--\ base 165 2 2 -OCH 2

CH

2 - H H b CN N--\ base 166 2 2 -OCH 2

CH

2 - H H b CI N N \base 167 2 2 -OCH2CH2- H H 62 Base or No R m n A* R 2

R

3 R4 salt N \ base 168C 2 2 -OCH 2

CH

2 - H H

C

6

H

13 0 N--\ base 169 2 2 -OCH 2

CH

2 - H H

C

4 H0 Me base 170 Ci 2 2 -OCH 2

CH

2 - H H Me Me N base 171 Me-(\ 2 2 -OCH 2

CH

2 - H H base 172 N 2 2 -OCH 2

CH

2 - H H F F N base 173 F 2 2 -OCH 2

CH

2 - H H F CI Base 174 2 2 -OCH 2

CH

2 - H H Br NON base 175 F O 2 2 -OCH 2

CH

2

-

H H CN base 176 2 2 -OCH2CH2- H H N C N \base 177 2 2 -OCH 2

CH

2 - H H N--\ base 178 N 2 2 -OCH 2

CH

2 - H H ,s 63 Base or No R m n A* R 2

R

3 R4 salt 0 'Me base 179 2 2 -OCH 2

CH

2 - H H O-N N base 180 | 2 2 -OCH 2

CH

2 - H H CI O N base 181

NH

2 2 2 -OCH 2

CH

2 - H H -A CI 1N-\ base 182 O N 2 2 -OCH 2

CH

2 - H H H CN base N--\ 183 2 2 -OCH 2

CH

2 - H H

SO

2 Me N \ base 184 2 2 -OCH 2

CH

2 - H H j C3H 7 N-- base 185 o IZ ' 2 2 -OCH 2

CH

2 - H H b H NN--\ base 186 2 2 -OCH 2

CH

2 - H H b N-N N base 187 2 2 -OCH 2

CH

2 - H H s F 188 NC F 2 2 -OCH 2

CH

2 - H H base Me N base 189 Me 2 2 -OCH 2

CH

2 - H H Me 64 Base or No R m n A* R 2

R

3 R4 salt 190 O N -- \ H

CF

3

CO

2 H 190 N 2 2 -OCH 2

CH

2 - H H 2 2N2\ base 191 N 2 2 -OCH 2

CH

2 - H H N \base 192 N 2 2 -OCH2CH 2 - H H r-N, N--\ base 193 ', N -N 2 2 -OCH2CH2- H H base N 194 1 2 -OCH 2 - H H (R) Enantiomer I base N 195 1 2 -OCH 2 - H H (S) Enantiomer II base

N-

196 Cl 1 2 -OCH 2 - H H base F,, N 197 1 2 -OCH 2 - H H 198 F 2 2 -OCH2CH2- H H H2N 65 Base or No R m n A* R 2

R

3 R4 salt FT F 2O base 199 F- 2 2 -OCH2CH2- H H H2 N o base

H

2 N N 200 2 1 -OCH 2 - H H (R) (-) Enantiomer I Me 0 base

SH

2 N N, 201 0 2 1 -OCH 2 - H H O o base

H

2 N N 202 2 1 -OCH 2 - H H (S) (+) Enantiomer II The results of the 'H NMR analyses and the melting points (M.p.) for the compounds in Table 1 are given in the following Table 2. Table 2

N

o 1 H NMR 400 MHz d 6 -DMSO/CDCl 3 M.p. ( 0 C) 8.25 (m, 2H); 7.80 (d, 1H); 7.60 (m, 2H); 7.50 (d, 1 1H); 7.40 (d, 1H); 6.70 (d, 1H); 5.45 (s, 2H); 4.20 oil (m, 4H); 2.90 (m, 2H); 1.80 (m; 5H); 1.30 (m, 2H) 66 7.80 (d, 1H); 7.70 (d, 1H); 7.10 (m, 2H); 6.90 (m, 2 2H); 5.35 (s, 2H); 4.00 (m, 2H); 2.85 (m, 2H); 1.70 oil (m, 5H); 1.10 (m, 2H) 8.80 (s, 1H); 7.40 (s, 1H); 7.00 (m, 2H); 6.85 (m, 3 2H); 5.30 (s, 2H); 4.20 (m, 2H); 4.00 (m, 2H); 2.80 76-78 (m, 2H); 1.70 (m, 5H); 1.25 (m, 2H) 9.10 (s, 1H), 7.65 (s, 1H); 7.60 (d, 2H); 7.10 (d, 4 2H); 5.20 (s, 2H); 4.10 (m, 2H); 4.00 (m, 2H); 2.80 oil (m, 2H); 1.70 (m, 5H); 1.15 (m, 2H) 9.10 (s, 1H); 7.65 (s, 1H); 7.30 (d, 2H); 6.90 (d, 5 2H); 5.10 (s, 2H); 3.90 (m, 4H); 2.80 (m, 2H); 1.70 53-55 (m, 4H); 1.10 (m, 2H) 8.80 (s, 1H); 7.90 (s, 1H); 7.00 (m, 2H); 6.80 (m, 6 2H); 5.30 (s, 2H); 4.20 (m, 2H); 4.00 (m, 2H); 2.80 96-98 (m, 2H); 1.75 (m, 6H); 1.20 (m, 2H) 9.10 (s, 1H); 7.90 (s, 1H); 7.30 (d, 2H); 6.95 (d, 7 2H); 5.30 (s, 2H); 3.90 (m, 4H); 2.80 (m, 2H); 1.60 93-97 (m, 6H); 1.10 (m, 2H) 9.10 (s, 1H); 7.95 (s, 1H); 7.60 (d, 2H); 7.10 (d, 8 2H); 5.30 (s, 2H); 4.10 (m, 2H); 3.95 (m, 2H); 2.80 47-49 (m, 2H); 1.65 (m, 6H); 1.10 (m, 2H) 9.10 (s, 1H); 7.75 (s, 1H); 7.70 (m, 2H); 7.20 (m, 2H); 6.95 (m, 2H); 5.15 (s, 2H); 4.10 (m, 2H); 4.00 9 95-97 (m, 2H); 3.80 (s, 3H); 2.80 (m, 2H); 1.70 (m, 5H); 1.15 (m, 2H) 8.80 (s, 1H); 7.60 (d, 2H); 7.40 (s, 1H); 6.95 (d, 10 2H); 5.30 (s, 2H); 4.20 (m, 2H); 4.05 (m, 2H); 2.80 108-110 (m, 2H); 1.75 (m, 5H); 1.20 (m, 2H) 8.80 (s, 1H); 7.65 (m, 2H); 7.40 (s, 1H); 7.10 (m, 4H), 5.30 (s, 2H); 4.05 (m, 2H); 3.90 (s, 3H); 11 128-130 3.80-3.35 (m, 4H); 2.80 (m, 1H); 2.20 (m, 1H); 1.90 (m, 1H) 8.80 (s, 1H); 7.70 (m, 2H); 7.40 (s, 1H); 7.05 (m, 4H), 5.35 (s, 2H); 4.10 (m, 2H); 3.90 (s, 3H); 3.80 12 112-114 (m, 1H); 3. 65 (m, 1H) ; 3.55 (m, 1H); 3.40 (m, 1H); 2.80 (m, 1H); 2.20 (m, 1H); 1.90 (m, 1H) 8.80 (s, 1H); 7.40 (s, 1H); 7.35 (d, 1H); 7.00 (s, 1H); 6.75 (d, 1H); 5.30 (s, 2H); 3.90 (m, 2H); 3.70 13 78-80 (m, 1H); 3.60 (m, 1H); 3.50 (m, 1H); 3.30 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 67 8.80 (s, 1H); 7.65 (m, 2H); 7.40 (s, 1H); 7.10 (m, 14 4H); 5.30 (s, 2H); 4.20 (m, 2H); 4.10 (m, 2H); 3.90 100-102 (s, 3H); 2.80 (m, 2H); 1.80 (m, 5H); 1.25 (m, 2H) 8.80 (s, 1H); 7.80 (m, 3H); 7.45 (m, 1H); 7.40 (m, 15 2H); 7.15 (m, 2H); 5.30 (s, 2H); 4.25 (m, 2H); 4.20 88-90 (m, 2H); 2.90 (m, 2H); 1.85 (m, 5H); 1.25 (m, 2H) 9.10 (m, 1H); 8.50 (m, 2H); 7.95 (m, 1H); 7.85 (m, 1H); 7.75 (d, 1H); 7.70 (m, 1H); 7.00 (d, 1H); 5.60 16 (s, 2H); 4.40 (m, 2H); 4.10 (m, 1H); 4.00 (m, 1H); 84-86 3.85 (m, 1H); 3.70 (m, 1H); 3.20 (m, 1H); 2.50 (m, 1H); 2.30 (m, 1H) 9.10 (s, 1H); 7.85 (m, 3H); 7.70 (m, 1H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 5.20 (s, 2H); 4.10 17 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 90-92 3.30 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 8.80 (s, 1H); 7.50 (m, 4H); 7.40 (s, 1H); 7.10 (m, 18 2H); 6.95 (d, 2H); 5.30 (s, 2H); 4.20 (m, 2H); 4.10 62-64 (m, 2H); 2.85 (m, 2H); 1.80 (m, 5H); 1.25 (m, 2H) 9.10 (s, 1H); 9.05 (m, 1H); 8.80 (d, 1H); 8.20 (d, 1H); 7.90 (m, 1H); 7.70 (m, 3H); 5.20 (s, 2H); 4.25 19 140-150 (m, 2H); 4.00 (m, 2H); 2.85 (m, 2H); 1.80 (m, 5H); 1.15 (m, 2H) 9.70 (s, 1H); 9.10 (s, 1H); 8.60 (d, 1H); 8.45 (d, 1H); 8.30 (d, 1H); 7.80 (s, 1H); 7.70 (m, 2H); 5.20 20 150-160 (s, 2H); 4.35 (m, 2H); 4.00 (m, 2H); 2.85 (m, 2H); 1.80 (m, 5H); 1.20 (m, 2H) 9.10 (s, 1H); 8.20 (s, 1H); 8.10 (d, 1H); 7.85 (d, 1H); 7.70 (m, 2H); 7.40 (m, 1H); 7.30 (m, 2H); 7.00 21 (m, 1H); 5.20 (s, 2H); 4.10 (m, 2H); 3.60 (m, 1H); oil 3.50 (m, 1H); 3.40 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 7.70 (m, 3H); 7.60 (d, 2H); 7.30 (m, 2H); 7.05 (m, 2H); 5.20 (s, 2H); 4.05 (m, 2H); 3.60 22 115-117 (m, 1H); 3.50 (m, 1H); 3.35 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 8.10 (d, 1H); 7.80 (d, 1H); 7.70 (m, 1H); 7.50 (m, 3H); 7.30 (d, 1H); 5.20 (s, 2H); 4.15 23 89-91 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 3.25 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.80 (m, 68 1H) 9.10 (s, 1H); 7.70 (s, 1H); 7.40 (m, 1H); 7.05 (m, 1H); 6.95 (m, 2H); 5.20 (s, 2H); 4.05 (m, 2H); 3.60 24 54-56 (m, 1H); 3.50 (m, 1H); 3.35 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 7.70 (s, 1H); 7.30-7.10 (m, 7H); 6.90 (m, 2H); 5.20 (s, 2H); 4.00 (m, 2H); 3.60 (m, 1H); 25 76-78 3.50 (m, 1H); 3.35 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.05 (m, 1H); 1.75 (m, 1H); 1.60 (s, 6H) 9.10 (s, 1H); 8.70 (s, 1H); 8.00 (d, 1H); 7.90 (m, 1H); 7.80 (m, 1H); 7.70 (m, 1H); 7.60 (m, 2H); 5.20 26 (s, 2H); 4.20 (m, 2H); 3.65 (m, 1H); 3.55 (m, 1H); 83-85 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) 9.20 (s, 1H); 9.10 (m, 1H); 8.40 (d, 1H); 8.05 (d, 1H); 7.70 (m, 2H); 7.40 (m, 1H); 7.30 (d, 1H); 5.20 27 (s, 2H); 4.20 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 122-124 3.40 (m, 1H); 3.30 (m, 1H); 2.75 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 8.80 (s, 1H); 8.30 (d, 1H); 7.90 (d, 1H); 7.70 (m, 1H); 7.40 (m, 2H); 7.30 (d, 1H); 5.20 28 (s, 2H); 4.20 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 94-96 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.20 (s, 1H); 9.10 (s, 1H); 8.40 (d, 1H); 7.90 (d, 1H); 7.80 (d, 1H); 7.70 (m, 1H); 7.55 (s, 1H); 7.45 29 (d, 1H); 5.20 (s, 2H); 4.20 (m, 2H); 3.60 (m, 1H); 121-123 3.50 (m, 1H); 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 7.65 (m, 2H); 7.40 (s, 1H); 7.30 (d, 1H); 5.20 (s, 2H); 4.10 (m, 2H); 3.60 (m, 1H); 3.50 30 60-62 (m, 1H); 3.40 (m, 1H); 3.20 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 9.10 (s, 1H); 8.00 (d, 1H); 7.70 (m, 2H); 7.50 (m, 2H); 7.30 (d, 1H); 7.15 (m, 1H); 5.20 (s, 2H); 4.15 31 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 76-78 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) 69 7.90 (m, 4H); 7.75 (d, 1H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (d, 1H); 5.35 (s, 2H); 4.15 (m, 2H); 3.65 194 100-112 (m, 1H); 3.55 (m, 1H); 3.45 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.15 (m, 1H); 1.85 (m, 1H) 7.90 (m, 4H); 7.75 (d, 1H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (d, 1H); 5.35 (s, 2H); 4.15 (m, 2H); 3.65 195 112-114 (m, 1H); 3.55 (m, 1H); 3.45 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.15 (m, 1H); 1.85 (m, 1H) 8.10 (d, 1H); 7.85 (m, 2H); 7.75 (d, 1H); 7.50 (m, 3H); 7.40 (d, 1H); 5.35 (s, 2H); 4.20 (m, 2H); 3.65 196 100-102 (m, 1H); 3.55 (m, 1H); 3.45 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.15 (m, 1H); 1.85 (m, 1H) 7.85 (m, 1H); 7.75 (m, 1H); 7.65 (m, 2H); 7.60 (d, 2H); 7.30 (m, 2H); 7.05 (d, 2H); 5.40 (s, 2H); 4.10 197 (m, 2H); 3.60 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 81-83 3.30 (m, 1H); 2.70 (m, 1H); 2.10 (m, 1H); 1.80 (m, 1H) 8.15 (bs, 1H); 7.85 (bs, 1H); 7.15 (m, 2H); 7.00 198 (m, 2H); 6.80 (s, 1H); 5.25 (s, 2H); 4.00 (m, 4H); 106-108 2.90 (m, 2H); 1.70 (m, 5H); 1.10 (m, 2H) 8.15 (bs, 1H); 7.85 (bs, 1H); 7.30 (d, 2H); 7.05 199 (d, 2H); 6.80 (s, 1H); 5.25 (s, 2H); 4.05 (m, 4H); 112-115 2.85 (m, 2H); 1.70 (m, 5H); 1.10 (m, 2H) 8.15 (bs, 1H); 7.80 (m, 4H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 6.80 (s, 1H); 5.30 (s, 2H); 4.10 200 (m, 2H); 3.65 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 138-140 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) 8.15 (bs, 1H); 8.85 (bs, 1H); 8.75 (m, 2H); 7.30 (m, 2H); 7.20 (m, 2H); 6.80 (s, 1H); 5.30 (s, 2H); 201 4.10 (m, 2H); 3.90 (s, 3H); 3.60 (m, 1H); 3.50 (m, 193-195 1H); 3.40 (m, 1H); 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) 8.15 (bs, 1H); 7.80 (m, 4H); 7.50 (m, 1H); 7.35 (m, 2H); 7.20 (m, 1H); 6.80 (s, 1H); 5.30 (s, 2H); 4.10 202 (m, 2H); 3.65 (m, 1H); 3.50 (m, 1H); 3.40 (m, 1H); 139-141 3.30 (m, 1H); 2.80 (m, 1H); 2.10 (m, 1H); 1.85 (m, 1H) The results for the masses M+H measured by LC-MS and the 70 retention times for the compounds in Table 1 are given in the following Table 3. LC-MS conditions: Method A: HPLC/ZQ - Gradient 10 min Mobile phases: Phase A: CH 3

COONH

4 + 3% ACN Phase B: ACN Stationary phase/column: Kromasil C18 column Dimensions: 50*2.1 mm; 3.5 pm Flow rate: D = 0.8 ml/min Temperature of the column: T = 40'C Injection volume: V = 5 pl Gradient: T = 0 min: 100% of A, from T = 5.5 min to T = 7 min: 100% of B, from T = 7.1 min to T = 10 min: 100% of A. Method B: UPLC/TOF - Gradient 3 min Mobile phases: Phase A: H 2 0 + 0.05% of TFA Phase B: ACN + 0.035% of TFA Stationary phase/column: Acquity BEH C18 column Dimensions: 50*2.1 mm; 1.7 pm Flow rate: D = 1.0 ml/min Temperature of the column: T = 40'C Injection volume: V = 2 pl Gradient: T = 0 min: 98% of A and 2% of B, from T = 1.6 min to T = 2.1 min: 100% of B, from T = 2.5 min to T = 3 min: 98% of A and 2% of B. Method C: LC/TRAP - Gradient 20 min Mobile phases: H 2 0/CH 3

COONH

4 /ACN Stationary phase/column: Kromasil C18 column 71 Method D: LC/ZQ - Gradient 20 min Mobile phases: TFA/ACN Stationary phase/column: Kromasil C18 column Method E: LC/TOF - Gradient 20 min Mobile phases: H 2 0/CH 3

COONH

4 /ACN Stationary phase/column: Kromasil C18 column Method F: Stationary phase/column: Jsphere Dimensions: 33*2 mm; 4 pm Gradient: H 2 0 + 0.05% TFA:ACN + 0.05% TFA; 2:98 (1 min) to 95:5 (5.0 min) to 95:5 (6.25 min). Method G: Stationary phase/column: Waters XBridge C18 Dimensions: 4.6*50 mm; 2.5 pm Gradient: H 2 0 + 0.05% TFA:ACN + 0.05% TFA; 95:5 (0 min) to 95:5 (0.3 min) to 5:95 (3.5 min) to 5:95 (4 min). Method H: YMC Stationary phase/column: Jsphere Dimensions: 33*2 mm; 4 pm Gradient: H 2 0 + 0.1% TFA:ACN + 0.08% TFA; 95:5 (0 min) to 5:95 (2.5 min) to 5:95 (3 min).

72 Table 3 N* Method M+H Retention time 1. D 431 10.40 2. A 365 9.70 3. D 365 8.80 4. D 415 10.00 5. D 381 9.80 6. D 365 9.00 7. D 381 9.70 8. C 415 10.50 9. D 427 10.00 10. D 372 8.30 11. E 399 8.50 12. D 387 10.50 13. D 387.01 10.00 14. D 427 11.10 15. D 397 11.50 16. D 403 10.00 17. D 369 8.90 18. D 441 10.70 19. D 398 5.70 20. D 398 5.80 21. D 420 9.40 22. D 413 10.00 23. D 403 10.40 24. D 403 9.60 25. D 437 11.00 26. D 370 6.00 27. D 370 5.30 28. D 370 5.20 29. D 370 5.30 30. D 421 10.10 31. D 387 9.90 32. F 375.12 4.20 33. F 414.98 4.10 34. F 414.98 4.19 35. F 414.97 4.11 36. F 414.99 4.17 73 37. F 415.03 4.30 38. F 415.16 4.60 39. F 464.05 3.95 40. F 453.10 4.17 41. F 404.09 2.81 42. F 398.09 2.52 43. F 398.07 2.50 44. F 390.04 3.55 45. F 423.09 4.14 46. F 403.15 4.44 47. F 415.06 4.07 48. F 459.19 4.90 49. F 437.16 4.29 50. F 412.09 3.93 51. F 390.10 2.86 52. F 372.07 3.72 53. F 459.21 5.15 54. F 437.15 4.27 55. H 454.41 2.01 56. F 455.09 3.89 57. F 439.09 4.19 58. F 398.08 2.51 59. F 447.16 4.73 60. F 419.15 4.29 61. F 398.07 2.55 62. F 465.04 4.27 63. F 454.08 3.17 64. F 460.92 4.14 65. F 412.08 2.51 66. F 448.07 4.04 67. F 422.06 3.78 68. F 430.01 3.65 69. F 423.12 4.24 70. F 423.11 4.22 71. F 423.05 3.39 72. F 406.01 3.66 73. F 418.03 3.56 74. F 448.07 3.94 75. F 432.10 2.82 74 76. F 448.00 3.92 77. F 375.12 4.04 78. F 415.00 3.91 79. F 397.11 4.08 80. F 390.13 2.59 81. F 415.06 3.97 82. F 437.11 4.19 83. F 391.12 3.55 84. F 465.20 4.44 85. F 439.09 4.17 86. F 442.97 3.80 87. G 437.11 3.87 88. G 439.10 3.77 89. G 447.11 4.16 90. G 419.12 3.85 91. G 437.03 4.26 92. G 465.01 3.79 93. G 454.11 2.85 94. G 460.94 3.76 95. F 448.11 3.56 96. G 422.09 4.31 97. G 430.04 3.23 98. G 423.10 3.79 99. G 423.10 3.78 100. G 406.03 3.33 101. G 418.05 3.15 102. G 448.09 3.51 103. G 432.12 2.57 104. G 448.03 3.53 105. F 404.13 2.55 106. F 397.07 3.99 107. F 397.08 4.13 108. F 427.08 4.03 109. G 415.11 4.08 110. G 453.13 3.63 111. G 398.11 2.39 112. G 398.11 2.37 113. G 412.14 2.38 114. G 423.08 3.08 75 115. H 415.27 2.49 116. H 415.27 2.49 117. H 464.38 2.34 118. H 390.33 2.12 119. H 459.45 3.04 120. H 412.36 2.37 121. H 459.45 2.92 122. H 404.39 1.35 123. H 412.36 1.36 124. H 372.32 2.10 125. F 347.16 3.55 126. F 423.20 4.12 127. F 390.2 2.71 128. F 365.15 3.60 129. F 375.20 4.06 130. F 404.24 2.49 131. G 415.04 3.95 132. F 415.10 4.01 133. F 415.09 3.99 134. F 415.12 4.15 135. H 415.11 4.38 136. F 397.20 3.94 137. F 397.19 3.97 138. F 412.20 2.43 139. F 464.19 3.85 140. F 453.21 4.09 141. F 426.16 2.82 142. F 398.18 2.48 143. F 404.20 2.81 144. F 398.19 2.47 145. F 398.19 2.50 146. F 398.17 2.40 147. F 390.22 2.57 148. F 390.16 3.46 149. F 423.18 4.06 150. F 423.20 4.09 151. F 415.12 3.88 152. F 437.22 4.13 153. F 391.20 3.53 76 154. F 415.27 4.41 155. F 465.29 4.42 156. F 439.20 4.08 157. F 443.06 3.87 158. F 412.21 3.85 159. F 372.17 3.43 160. F 459.33 4.84 161. F 437.23 4.15 162. F 453.21 3.89 163. F 423.18 3.37 164. F 455.2 3.70 165. F 439.20 4.05 166. F 406.13 3.55 167. F 398.18 2.49 168. F 447.29 4.55 169. F 419.27 4.25 170. F 437.23 4.56 171. F 418.15 3.37 172. F 398.18 2.52 173. F 465.15 4.07 174. F 461.03 4.08 175. F 413.15 3.69 176. F 448.20 3.86 177. F 422.07 3.76 178. F 430.14 3.53 179. F 427.21 3.88 180. F 448.15 3.81 181. F 424.15 3.04 182. F 454.23 3.11 183. F 448.20 3.99 184. F 425.16 3.00 185. F 446.13 3.44 186. F 386.2 3.36 187. F 431.19 3.19 188. F 390.15 3.36 189. F 403.28 4.34 190. F 432.22 2.72 191. F 412.20 2.49 192. F 430.21 3.05 77 193. F 415.20 3.17 194. D 369 4.70 195. D 369 4.73 196. A 403 5.08 197. A 413 5.00 198. B 392 1.14 199. B 458 1.28 200. B 396 1.15 201. A 426 1.13 202. B 396 1.15 The compounds of the invention form the subject of pharmacological trials which make it possible to determine their inhibitory effect on the enzyme FAAH (Fatty Acid Amide Hydrolase). 1/ Radioenzymatic test The inhibitory activity was demonstrated in a radioenzymatic test based on the measurement of the product of hydrolysis of anandamide [ethanolamine 1- 3 H] by FAAH (Life Sciences (1995), 56, 1999-2005 and Journal of Biochemical and Biophysical Methods (2004) , 60 (2) , 171-177) . Thus, mouse brains (minus the cerebellum) are removed and stored at -80 0 C. The membrane homogenates are prepared at the time of use by homogenization of the tissues using a Precellys@ device in the reaction buffer (Tris-HCl 10 mM pH=8, NaCl 150 mM and ethylenediaminetetraacetic acid (EDTA) 1 mM). The enzymatic reaction is carried out in 96-well MultiScreen filtration plates in a final volume of 70 pl. Reaction buffer supplemented with bovine serum albumin free from fatty acids (BSA, 1 mg/ml) is used for the enzymatic reaction, the dilution of the compounds and the dilution of the anandamide [ethanolamine 1- 3 H]. Reaction buffer comprising the BSA (43 pl/well), the diluted test compounds at different 78 concentrations (7 pl/well comprising 1% of DMSO) and the membrane preparation (10 pl/well, i.e. 200 pg of tissue per trial) are successively added to the wells. After preincubating the compounds with the enzyme at 25 0 C for 20 minutes, the reaction is initiated by the addition of anandamide [ethanolamine 1- 3 H] (specific activity of 15 20 Ci/mmol) diluted with cold anandamide (10 pl/well, final concentration of 10 pM, 0.01 pCi, per trial) . After incubating at 25 0 C for 20 minutes, the enzymatic reaction is halted by addition of a 5M active charcoal solution prepared in a 1.5M NaCl and 0.5M HCl buffer (50 pl/well) . The mixture is stirred for 10 minutes and then the aqueous phase comprising the [1 3 H]ethanolamine is recovered by filtration under vacuum and counted by liquid scintillation. Under these conditions, the most active compounds of the invention exhibit CIso values (concentration which inhibits the control enzymatic activity of FAAH by 50%) of between 0.1 and 1000 nM, preferably between 0.1 and 500 nM, preferably between 0.2 and 100 nM, indeed even between 0.2 and 50 nM. For example, compounds No. 26, No. 38, No. 39, No. 49, No. 60, No. 90, No. 196, No. 199, No. 200 and No. 202 have respective CIs 0 values of 86 nM, 14 nM, 13 nM, 19 nM, 95 nM, 92 nM, 252 nM, 350 nM, 122 nM and 8 nM. It is thus apparent that the compounds according to the invention have an inhibitory activity on the enzyme FAAH. The in vivo activity of the compounds of the invention can be evaluated in a test for analgesia. 2/ Test for analgesia The intraperitoneal (i.p.) administration of PBQ (phenylbenzoquinone, 2 mg/kg in a 0.9% sodium chloride 79 solution comprising 5% of ethanol) to male OF1 mice weighing 25 to 30 g causes abdominal tractions, on average 30 twisting or contracting motions during the period from 5 to 15 minutes after injection. The test compounds are administered, orally (p.o.) or intraperitoneally (i.p.) in suspension in 0.5% Tween 80, 60 minutes or 120 minutes before the administration of PBQ. Under these conditions, the most powerful compounds reduce by 30 to 80% the number of tractions induced by the PBQ, within a range of doses of between 1 and 30 mg/kg. The enzyme FAAH (Chemistry and Physics of Lipids, (2000), 108, 107-121) catalyses the hydrolysis of endogenous derivatives of amides and esters of various fatty acids, such as N-arachidonoylethanolamine (anandamide), N-palmitoyl ethanolamine, N-oleoylethanolamine, oleamide or 2-arachidonoylglycerol. These derivatives exert various pharmacological activities by interacting, inter alia, with the cannabinoid and vanilloid receptors. The compounds of the invention block this decomposition pathway and increase the tissue level of these endogenous substances. They can therefore be used in the prevention and treatment of pathologies in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FAAH are involved. Mention may be made, for example, of the following diseases and conditions: pain, in particular acute or chronic pain of neurogenic type: migraine, neuropathic pain, including forms associated with the herpes virus and with diabetes and with chemotherapy; acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; acute or chronic peripheral pain; dizziness, vomiting, nausea, in particular resulting from chemotherapy; eating disorders, 80 in particular anorexia and cachexia of various natures; neurological and psychiatric pathologies: tremors, dyskinesias, dystonias, spasticity, obsessive-compulsive behaviour, Tourette's syndrome, all forms of depression and of anxiety of any nature and origin, mood disorders, psychoses; acute or chronic neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions related to cerebral ischaemia and to cranial and medullary trauma; epilepsy; sleep disorders, including sleep apnoea; cardiovascular diseases, in particular hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischaemia; renal ischaemia; cancers: benign skin tumours, brain tumours and papillomas, prostate tumours, cerebral tumours (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumours of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, plexus tumour, neuroepitheliomas, epiphyseal tumour, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas); disorders of the immune system, in particular autoimmune diseases: psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjbgren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune haemolytic anaemia, multiple sclerosis, amyotrophic lateral sclerosis, amyloidosis, graft rejection, diseases affecting the plasmocytic line; allergic diseases: immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis; parasitic, viral or bacterial infectious diseases: AIDS, meningitis; inflammatory diseases, in particular joint diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome; osteoporosis; eye conditions: ocular hypertension, glaucoma; pulmonary conditions: diseases of the respiratory tract, bronchospasm, coughing, asthma, chronic 81 bronchitis, chronic obstruction of the respiratory tract, emphysema; gastrointestinal diseases: irritable bowel syndrome, inflammatory intestinal disorders, ulcers, diarrhoea; urinary incontinence and bladder inflammation. The use of the compounds according to the invention, in the form of the base, of an addition salt with an acid, of a hydrate or of a solvate which is pharmaceutically acceptable, in the preparation of a medicament intended to treat the abovementioned pathologies forms an integral part of the invention. Compounds according to the invention, in the form of the base, of an addition salt with an acid, of a hydrate or of a solvate which is pharmaceutically acceptable, for their use in the preparation of a medicament intended to treat the abovementioned pathologies forms an integral part of the invention. Another subject-matter of the invention is medicaments which comprise a compound of formula (I), (Ii) or (Iii), or an addition salt with an acid, or a hydrate or a solvate which is pharmaceutically acceptable of the compound of formula (I), (Ii) or (Iii) . These medicaments are used therapeutically, in particular in the treatment of the abovementioned pathologies. According to another of its aspects, the present invention relates to pharmaceutical compositions including, as active principle, at least one compound according to the invention. These pharmaceutical compositions comprise an effective dose of a compound according to the invention, or an addition salt with an acid, or a hydrate, or a solvate which is pharmaceutically acceptable of the said compound, and optionally one or more pharmaceutically acceptable excipients.

82 The said excipients are chosen, depending on the pharmaceutical form and the method of administration desired, from the usual excipients which are known to a person skilled in the art. In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intrathecal, intranasal, transdermal, pulmonary, ocular or rectal administration, the active principle of formula (I), (Ii) or (Iii) above or its optional addition salt with an acid, solvate or hydrate can be administered in a unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to man for the prophylaxis or the treatment of the above disorders or diseases. Appropriate unit administration forms comprise oral forms, such as tablets, soft or hard gelatin capsules, powders, granules, chewing gums and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular or intranasal administration or for administration by inhalation, forms for subcutaneous, intramuscular or intravenous administration and forms for rectal or vaginal administration. For topical application, the compounds according to the invention can be used in creams, ointments or lotions. By way of example, a unit administration form of a compound according to the invention in the form of a tablet can comprise the following components: Compound according to the invention 50.0 mg Mannitol 223.75 mg Croscarmellose sodium 6.0 mg Maize starch 15.0 mg 83 Hydroxypropylmethylcellulose 2.25 mg Magnesium stearate 3.0 mg The said unit forms comprise a dose which makes possible a daily administration of 0.01 to 20 mg of active principle per kg of body weight, depending upon the pharmaceutical dosage form. There may be specific cases where higher or lower dosages are appropriate; such dosages also come within the invention. According to the usual practice, the dosage appropriate to each patient is determined by the doctor according to the method of administration and the weight and the response of the said patient. According to another of its aspects, the invention also relates to a method for the treatment of the pathologies indicated above which comprises the administration of an effective dose of a compound according to the invention, of one of its addition salts with a pharmaceutically acceptable acid or of a solvate or of a hydrate of the said compound.

Claims

1. Compound corresponding to the general formula (I): 0 R3 R2pw 2r N O J-R4 R'A (I) in which: - R 2 represents a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1 - 6 -alkyl, C 1 - 6 -alkoxy or -NR 8 R 9 group; - n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; - A represents a covalent bond, an oxygen atom, a C 1 - 6 -alkylene group or an -O-Ci_ 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group; - Ri represents an R 5 group optionally substituted by one or more R 6 and/or R 7 groups; R 5 representing a group chosen from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, isobenzofuranyl, benzofuranyl, benzothiophenyl, benzothiadiazolyl, benzoxadiazolyl, indazolyl, indolizinyl, indolyl, isoindolyl, imidazopyridinyl, imidazopyrimidinyl, imidazopyrazinyl, imidazopyridazinyl, triazolopyridinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyrazinyl, pyrrolopyridazinyl, pyrrolotriazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyrazinyl, pyrazolopyridazinyl, furopyridinyl, furopyrimidinyl, furopyrazinyl, furopyridazinyl, furotriazinyl, oxazolopyridinyl, oxazolopyrimidinyl, oxazolopyrazinyl, 85 oxazolopyridazinyl, isoxazolopyridinyl, isoxazolopyrimidinyl, isoxazolopyrazinyl, isoxazolopyridazinyl, oxadiazolopyridinyl, thienopyridinyl, thienopyrimidinyl, thienopyrazinyl, thienopyridazinyl, thienotriazinyl, thiazolopyridinyl, thiazolopyrimidinyl, thiazolopyrazinyl, thiazolopyridazinyl, isothiazolopyridinyl, isothiazolopyrimidinyl, isothiazolopyrazinyl, isothiazolopyridazinyl or thiadiazolopyridinyl; R 6 representing a halogen atom or a cyano, -CH 2 CN, nitro, hydroxyl, C 1 - 8 -alkyl, C 1 - 6 -alkoxy, Ci--thioalkyl, Ci- 6 -haloalkyl, Ci- 6 -haloalkoxy, Ci--halothioalkyl, C 3 - 7 -cycloalkyl, C 3 - 7 -cycloalkyl-Ci_ 3 -alkylene, C 3 - 7 -cycloalkyl-Ci_ 3 -alkylene-O-, (CH 2 ) p-NR 8 R 9 , -NR 8 COR 9 , -NR 8 CO 2 R 9 , -NR 8 SO 2 R 9 , -NR 8 SO 2 NR 8 R 9 , -COR 8 , C0 2 R 8 , - (CH 2 ) p-CONR 8 R 9 , -S0 2 R 8 , -SO 2 NR 8 R 9 or -0- (Ci_ 3 -alkylene) -O group; R 7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 )p-O-, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, pyrrolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazopyrimidinyl, thienopyrimidinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, imidazopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, isoxazolopyridinyl or thiazolopyridinyl; it being possible for the R 7 group or groups to be substituted by one or more R 6 groups which are identical to or different from one another; p representing a number which can have the value 0, 1, 2 or 3; - R 3 represents a hydrogen or fluorine atom, a C 1 - 6 -alkyl group or a trifluoromethyl group; 86 - R 4 represents a 5-membered heterocycle chosen from a furanyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, triazolyl or tetrazolyl; this heterocycle optionally being substituted by one or more substituents chosen from a halogen atom or a C 1 6 -alkyl, C 1 6 haloalkyl, C 3 - 7 -cycloalkyl, C 3 - 7 -cycloalkyl-Ci_ 3 -alkylene, C 1 6 haloalkoxy, cyano, -NR 8 R 9 , -NR 8 C (0) R 9 , -NR 8 CO 2 R 9 , -NR 8 SO 2 R 9 , -NR 8 SO 2 NR 8 R 9 , -C (O) R 8 , -C0 2 R 8 , -C (O) NR 8 R 9 , -C (0) N (R 8 ) (Ci_ 3 -alkylene-NRioRii), -S0 2 R 8 , -SO 2 NR 8 R 9 or -0- (Ci_ 3 alkylene)-0- group; R 8 and R 9 representing, independently of one another, a hydrogen atom or a C 1 - 6 -alkyl group, or forming, with the nitrogen atom or atoms which carry them, in the case of NR 8 R 9 , a ring chosen from the azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine, oxazepine or piperazine rings, this ring optionally being substituted by a C 1 - 6 -alkyl or benzyl group; in the case of NR 8 COR 9 , a lactam ring; in the case of NR 8 CO 2 R 9 , an oxazolidinone, oxazinone or oxazepinone ring; in the case of NR 8 SO 2 R 9 , a sultam ring; in the case of NR 8 SO 2 NR 8 R 9 , a thiazolidine dioxide or thiadiazinane dioxide ring; Rio and R 11 representing, independently of one another, a hydrogen atom or a C 1 6 -alkyl group; with the exclusion of the following compound:

5-methylisoxazol-3-ylmethyl 4-hydroxy-4-(4-chlorophenyl) piperidine-1-carboxylate, in the form of the base or of an addition salt with an acid. 2. Compound of formula (I) according to Claim 1, wherein R 2 represents a hydrogen atom; in the form of the base or of an addition salt with an acid. 87 3. Compound of formula (I) according to Claim 1 or 2, wherein m and n represent, independently of one another, the value 1 or 2; in the form of the base or of an addition salt with an acid. 4. Compound of formula (I) according to any one of the preceding claims, wherein A represents an -O-Ci- 6 -alkylene group in which the end represented by an oxygen atom is bonded to the Ri group; in the form of the base or of an addition salt with an acid. 5. Compound of formula (I) according to any one of the preceding claims, wherein Ri represents an R 5 group optionally substituted by one or more R 6 and/or R 7 groups; R 5 representing a group chosen from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, naphthyridinyl, benzothiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, isobenzofuranyl, benzofuranyl, benzothiophenyl, indazolyl, indolizinyl, indolyl, isoindolyl, pyrrolopyridinyl, furopyridinyl or thienopyridinyl; R 6 representing a halogen atom or a cyano, -CH 2 CN, nitro, hydroxyl, C 1 8 -alkyl, C 1 6 -alkoxy, C 1 6 -thioalkyl, C 1 6 -haloalkyl, C 1 6 -haloalkoxy, Ci_-halothioalkyl, C 3 - 7 -cycloalkyl, C 3 - 7 -cycloalkyl-Ci_ 3 -alkylene, C 3 - 7 -cycloalkyl-Ci_ 3 -alkylene-O-, (CH 2 )p-NR 8 R 9 , -NR 8 COR 9 , -NR 8 CO 2 R 9 , -NR 8 SO 2 R 9 , -NR 8 SO 2 NR 8 R 9 , -COR 8 , C0 2 R 8 , - (CH 2 ) p-CONR 8 R 9 , -S0 2 R 8 , -SO 2 NR 8 R 9 or -0- (Ci_ 3 -alkylene) -O group; R 7 representing a group chosen from a phenyl, phenyl-Ci_ 4 alkylene-, phenyl- (CH 2 )p-O-, pyridinyl, pyridazinyl, isoxazolyl, benzothiazolyl, pyrrolyl, pyrazolyl, tetrazolyl, pyrimidinyl, thiazolyl, pyrazinyl, triazinyl or benzoxazolyl; 88 it being possible for the R 7 group or groups to be substituted by one or more R 6 groups, which are identical to or different from one another, as defined above; p representing a number which can have the value 0, 1, 2 or 3; R 8 and R 9 representing, independently of one another, a hydrogen atom or a C 1 - 6 -alkyl group; or forming, with the nitrogen atom or atoms which carry them, in the case of NR 8 R 9 , a ring chosen from the azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine, oxazepine or piperazine rings, this ring optionally being substituted by a C 1 - 6 -alkyl or benzyl group; in the case of NR 8 COR 9 , a lactam ring; in the case of NR 8 CO 2 R 9 , an oxazolidinone, oxazinone or oxazepinone ring; in the case of NR 8 SO 2 R 9 , a sultam ring; in the case of NR 8 SO 2 NR 8 R 9 , a thiazolidine dioxide or thiadiazinane dioxide ring; in the form of the base or of an addition salt with an acid.

6. Compound of formula (I) according to any one of the preceding claims, wherein R 3 represents a hydrogen atom; in the form of the base or of an addition salt with an acid.

7. Compound of formula (I) according to any one of the preceding claims, wherein R 4 represents a 5-membered heterocycle chosen from a thiazolyl or isoxazolyl; this heterocycle optionally being substituted by one or more C(O)NR 8 R 9 substituents in which R 8 and R 9 each represent a hydrogen atom; in the form of the base or of an addition salt with an acid.

8. Compound of formula (I) according to claim 1 which is 89 chosen among the following compounds Thiazol-2-ylmethyl 4-[2-(4-chloronaphth-1-yloxy)ethyl] piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-fluorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-fluorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-{trifluoromethyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-chlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-fluorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-chlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-{trifluoromethyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy)ethyl] piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-cyanophenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl (+/-)-3-(6-methoxynaphth-2-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(7-methoxynaphth-2-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(3,4-dichlorophenoxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(6-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate 90 Thiazol-4-ylmethyl 4-[2-(naphth-2-yloxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl (+/-)-3-(4-chloronaphth-1-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4'-fluorobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl]piperidine-1 carboxylate and its hydrochloride Thiazol-4-ylmethyl 4-[2-(isoquinolin-6-yloxy)ethyl]piperidine-1 carboxylate and its hydrochloride Thiazol-4-ylmethyl (+/-)-3-(3'-cyanobiphenyl-3 yloxymethyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(5-chloronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(3-{trifluoromethoxy} phenoxymethyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-[4-(1-methyl-1-phenyl ethyl)phenoxymethyl]pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(quinolin-3-yloxymethyl)pyrrolidine 1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(isoquinolin-6-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(quinolin-7-yloxymethyl)pyrrolidine 1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(isoquinolin-7-yloxy methyl)pyrrolidine-1-carboxylate 91 Thiazol-4-ylmethyl (+/-)-3-(4-chloro-3-{trifluoro methyl}phenoxymethyl)pyrrolidine-1-carboxylate Thiazol-4-ylmethyl (+/-)-3-(5-fluoronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(2,5-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(3,4-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(3,5-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(4-cyclopentylphenoxy)ethylipiperidine 1-carboxylate Thiazol-2-ylmethyl 4-[2-(2-{benzoxazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-{benzyloxy}phenoxy)ethylipiperidine 1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-{carbamoylmethyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(quinolin-7-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate 92 Thiazol-2-ylmethyl 4-[2-(biphenyl-2-yloxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(2-isopropyl-5-methyl phenoxy)ethyl]piperidine-l-carboxylate Thiazol-2-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-{2-[4-(1,1,3,3-tetramethyl butyl)phenoxy]ethyl}piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(4-carbamoylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(3-cyanophenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(2-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(8-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(3-{methoxycarbonyl}naphth-2 yloxy)ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(4-hexyloxyphenoxy)ethyl]piperidine-1 carboxylate 93 Thiazol-2-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-l-carboxylate Thiazol-2-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy)ethylipiperidine 1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate 94 Thiazol-2-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-l-carboxylate Thiazol-4-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(naphth-1-yloxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(3-{dimethylamino}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(2-ethoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-{2-[4-(1-methyl-1-phenylethyl) phenoxy]ethyl}piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-phenoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(2-bromo-4-fluorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-{hexyloxy}phenoxy)ethyl]piperidine-1 carboxylate 95 Thiazol-4-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-chloro-5-isopropyl-2 methylphenoxy)ethyl]piperidine-l-carboxylate Thiazol-4-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy)ethylipiperidine 1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-1-carboxylate 96 Thiazol-2-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-2-ylmethyl 4-[2-(naphth-2-yloxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(naphth-1-yloxy)ethyl]piperidine-1 carboxylate Thiazol-2-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-cyclopentylphenoxy)ethylipiperidine 1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-benzyloxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl]piperidine-1 carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-4-ylmethyl 4-[2-(4-cyclopentylphenoxy)ethylipiperidine 1-carboxylate Thiazol-4-ylmethyl 4-[2-(2-{benzoxazol-2-yl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-{2-[4-(1,1,3,3-tetramethyl butyl)phenoxy]ethyl}piperidine-1-carboxylate 97 Thiazol-4-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-4-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(2-methylquinolin-8-yloxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-4-ylmethyl 4-[2-(3-cyanophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-(2-phenoxyethyl)piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(biphenyl-4-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-carbamoylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-fluorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2,4-dimethylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-{dimethylaminomethyl} phenoxy)ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-5-ylmethyl 4-[2-(2,3-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2,4-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2,5-dichlorophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3,5-dichlorophenoxy)ethyl]piperidine-1 carboxylate 98 Thiazol-5-ylmethyl 4-[2-(4-cyclopentylphenoxy)ethylipiperidine 1-carboxylate Thiazol-5-ylmethyl 4-[2-(naphth-2-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(naphth-1-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2-methylquinolin-8-yloxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-{benzoxazol-2-yl} phenoxy)ethyl]piperidine-l-carboxylate Thiazol-5-ylmethyl 4-[2-(4-{benzyloxy}phenoxy)ethylipiperidine 1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-sulphamoylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(isoquinolin-5-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-{carbamoylmethyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(quinolin-7-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(quinolin-6-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(quinolin-8-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3-{dimethylamino}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-5-ylmethyl 4-[2-(4-cyano-3-fluorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(biphenyl-2-yloxy)ethyl]piperidine-1 carboxylate 99 Thiazol-5-ylmethyl 4-[2-(biphenyl-3-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3-{trifluoromethyl} phenoxy)ethyl]piperidine-l-carboxylate Thiazol-5-ylmethyl 4-[2-(4-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2-ethoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2-cyclopentylphenoxy)ethylipiperidine 1-carboxylate Thiazol-5-ylmethyl 4-{2-[4-(1-methyl-1-phenylethyl) phenoxy]ethyl}piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-phenoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2-bromo-4-fluorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-{pyrrol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(3-cyanophenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3,5-di{tert-butyl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-benzylphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(2-{benzyloxy}phenoxy)ethylipiperidine 1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-cyanoquinolin-8-yloxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(3-{methoxycarbonyl}naphth-2 yloxy)ethyl]piperidine-1-carboxylate 100 Thiazol-5-ylmethyl 4-[2-(3-phenoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-chloro-2-cyanophenoxy) ethyl]piperidine-l-carboxylate Thiazol-5-ylmethyl 4-[2-(isoquinolin-7-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-{hexyloxy}phenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3-butoxyphenoxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(4-chloro-5-isopropyl-2 methylphenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-methylbenzothiazol-5 yloxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(quinolin-5-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-[2-(3-{pentafluoroethyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(5-bromo-2-chlorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-{difluoromethoxy}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4'-cyanobiphenyl-3-yloxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(6-cyanonaphth-2-yloxy)ethylipiperidine 1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-{thiazol-2-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(7-methoxynaphth-2-yloxy) ethyl]piperidine-1-carboxylate 101 Thiazol-5-ylmethyl 4-[2-(4-chloro-2-{isoxazol-5-yl} phenoxy)ethyl]piperidine-l-carboxylate Thiazol-5-ylmethyl 4-[2-(2-carbamoyl-4-chloro phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(5-{acetylamino}naphth-2 yloxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4'-cyanobiphenyl-4-yloxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-{methanesulphonyl} phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(5-acetylamino-2-propyl phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(1H-indol-6-yloxy)ethyl]piperidine-1 carboxylate Thiazol-5-ylmethyl 4-{2-[4-fluoro-2-(1H-pyrazol-3 yl)phenoxy]ethyl}piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(4-cyano-2-fluorophenoxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-isopropyl-5-methyl phenoxy)ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(2-{morpholin-4-yl}phenoxy) ethyl]piperidine-1-carboxylate and its trifluoroacetate Thiazol-5-ylmethyl 4-[2-(2-methylquinolin-6-yloxy) ethyl]piperidine-1-carboxylate Thiazol-5-ylmethyl 4-{2-[4-(2-oxopyrrolidin-1-yl) phenoxy]ethyl}piperidine-1-carboxylate Thiazol-5-ylmethyl 4-[2-(3-{tetrazol-1-yl}phenoxy) ethyl]piperidine-1-carboxylate Thiazol-2-ylmethyl (R)-3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate (enantiomer I) 102 Thiazol-2-ylmethyl (S)-3-(naphth-2-yloxymethyl)pyrrolidine-1 carboxylate (enantiomer II) Thiazol-2-ylmethyl (+/-)-3-(5-chloronaphth-2-yloxy methyl)pyrrolidine-1-carboxylate Thiazol-2-ylmethyl (+/-)-3-(4'-fluorobiphenyl-4 yloxymethyl)pyrrolidine-1-carboxylate 3-Carbamoylisoxazol-5-ylmethyl 4-[2-(4-fluoro phenoxy)ethyl]piperidine-1-carboxylate 3-Carbamoylisoxazol-5-ylmethyl 4-[2-(4-{trifluoro methoxy}phenoxy)ethyl]piperidine-1-carboxylate 3-Carbamoylisoxazol-5-ylmethyl (-)-(R)-3-(naphth-2 yloxymethyl)pyrrolidine-1-carboxylate (enantiomer I) 3-Carbamoylisoxazol-5-ylmethyl (+/-)-3-(6-methoxynaphth-2 yloxymethyl)pyrrolidine-1-carboxylate 3-Carbamoylisoxazol-5-ylmethyl (+)-(S)-3-(naphth-2 yloxymethyl)pyrrolidine-1-carboxylate (enantiomer II).

9. Compound according to any one of the preceding claims, wherein the compound is of formula (Ii): 0 (Ii) in which R 1 , A, R 4 , n and m are as defined in any one of the preceding claims; in the form of the base or of an addition salt with an acid.

10. Compound according to any one of the preceding claims, wherein the compound is of formula (Iii): 103 0 N Ok0 R AI m S' R 1(Iii) in which R 1 , A, n and m are as defined in any one of Claims 1 to 9; in the form of the base or of an addition salt with an acid.

11. Process for the preparation of a compound according to any one of Claims 1 to 10, comprising reacting an amine derivative, a compound of following general formula (II): R2 NH R 1 -A\ (Il) in which R 1 , R 2 , A, n and m are as defined in any one of the preceding claims, with a carbonate of following general formula (III): z0 O R O O R 4 (IlI) in which Z represents a hydrogen atom or a nitro group and R 3 and R 4 are as defined in any one of the preceding claims, in the presence of a base, in an organic solvent, at a temperature between ambient temperature and the reflux temperature of the solvent.

12. Process according to claim 11, wherein the base is triethylamine, pyridine, N, N-dimethylaminopyridine or N,N diisopropylethylamine.

13. Process according to claim 11 or claim 12, wherein the 104 organic solvent is toluene, acetonitrile or dichloroethane.

14. Compound according to any one of Claims 1 to 10, in the form of a base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for the use thereof as medicament.

15. Pharmaceutical composition comprising at least one compound according to any one of Claims 1 to 10, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, and optionally one or more pharmaceutically acceptable excipients.

16. Compound according to any one of Claims 1 to 10 in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for its use in the preparation of a medicament intended to prevent or to treat a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FAAH are involved.

17. Compound according to any one of Claims 1 to 10, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, for its use in the preparation of a medicament intended to prevent or treat acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or 105 bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation.

18. A method of preventing or treating a pathology in which endogenous cannabinoids and/or any other substrate metabolized by the enzyme FAAH are involved, the method comprising administering to a patient an effective dose of a compound according to any one of claims 1 to 10, in the form of the base or of an addition salt with a pharmaceutically acceptable acid or a hydrate or solvate of said compound.

19. A method of preventing or treating acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation, the method comprising administering to a patient an effective dose of a compound according to any one of claims 1 to 10, in the form of the base or of an addition salt with a pharmaceutically acceptable acid or a hydrate or solvate of said compound.

20. A use of a compound according to any one of claims 1 to 10, in the form of the base or of an addition salt with a pharmaceutically acceptable acid, or a hydrate or solvate thereof, in the manufacture of a medicament for preventing or 106 treating acute or chronic pain of neurogenic type, acute or chronic pain associated with inflammatory diseases, acute or chronic peripheral pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases, urinary incontinence or bladder inflammation in a patient.